<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="review-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Transl Lung Cancer Res</journal-id><journal-id journal-id-type="iso-abbrev">Transl Lung Cancer Res</journal-id><journal-id journal-id-type="pmc-domain-id">2705</journal-id><journal-id journal-id-type="pmc-domain">tlcr</journal-id><journal-id journal-id-type="publisher-id">TLCR</journal-id><journal-title-group><journal-title>Translational Lung Cancer Research</journal-title></journal-title-group><issn pub-type="ppub">2218-6751</issn><issn pub-type="epub">2226-4477</issn><publisher><publisher-name>AME Publications</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC10891406</article-id><article-id pub-id-type="pmcid-ver">PMC10891406.1</article-id><article-id pub-id-type="pmcaid">10891406</article-id><article-id pub-id-type="pmcaiid">10891406</article-id><article-id pub-id-type="pmid">38405003</article-id><article-id pub-id-type="doi">10.21037/tlcr-23-744</article-id><article-id pub-id-type="publisher-id">tlcr-13-01-163</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Review Article</subject></subj-group></article-categories><title-group><article-title>Lung cancer in females&#8212;sex-based differences from males in epidemiology, biology, and outcomes: a narrative review</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Gee</surname><given-names initials="K">Kaylan</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><xref rid="afn2" ref-type="author-notes">^</xref></contrib><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Yendamuri</surname><given-names initials="S">Sai</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff3" ref-type="aff">
<sup>3</sup>
</xref><xref rid="afn2" ref-type="author-notes">^</xref></contrib><aff id="aff1"><label>1</label><institution>Department of Thoracic Surgery</institution>, <addr-line>Roswell Park Comprehensive Cancer Center</addr-line>, <addr-line>Buffalo, NY</addr-line>, <country country="us">USA</country>;</aff><aff id="aff2"><label>2</label><institution content-type="dept">Department of Surgery</institution>, <institution>University of Tennessee Graduate School of Medicine</institution>, <addr-line>Knoxville, TN</addr-line>, <country country="us">USA</country>;</aff><aff id="aff3"><label>3</label><institution content-type="dept">Jacobs School of Medicine and Biomedical Sciences</institution>, <institution>State University of New York</institution>, <addr-line>Buffalo, NY</addr-line>, <country country="us">USA</country></aff></contrib-group><author-notes><fn id="afn1"><p><italic toggle="yes">Contributions:</italic> (I) Conception and design: Both authors; (II) Administrative support: S Yendamuri; (III) Provision of study materials or patients: None; (IV) Collection and assembly of data: K Gee; (V) Data analysis and interpretation: K Gee; (VI) Manuscript writing: Both authors; (VII) Final approval of manuscript: Both authors.</p></fn><corresp id="cor1"><italic toggle="yes">Correspondence to:</italic> Sai Yendamuri, MD, MBA. Department of Thoracic Surgery, Roswell Park Comprehensive Cancer Center, #717, Elm and Carlton Streets, Buffalo, NY 14203, USA; Jacobs School of Medicine and Biomedical Sciences, State University of New York, Buffalo, NY, USA. Email: <email xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="sai.yendamuri@roswellpark.org">sai.yendamuri@roswellpark.org</email>.</corresp><fn id="afn2"><label>^</label><p>ORCID: Kaylan Gee, 0009-0005-3888-1039; Sai Yendamuri, 0000-0001-6654-3487.</p></fn></author-notes><pub-date pub-type="epub"><day>29</day><month>1</month><year>2024</year></pub-date><pub-date pub-type="ppub"><day>31</day><month>1</month><year>2024</year></pub-date><volume>13</volume><issue>1</issue><issue-id pub-id-type="pmc-issue-id">456458</issue-id><fpage>163</fpage><lpage>178</lpage><history><date date-type="received"><day>15</day><month>11</month><year>2023</year></date><date date-type="accepted"><day>19</day><month>1</month><year>2024</year></date></history><pub-history><event event-type="pmc-release"><date><day>31</day><month>01</month><year>2024</year></date></event><event event-type="pmc-live"><date><day>25</day><month>02</month><year>2024</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-02-26 17:25:09.957"><day>26</day><month>02</month><year>2024</year></date></event></pub-history><permissions><copyright-statement>2024 Translational Lung Cancer Research. All rights reserved.</copyright-statement><copyright-year>2024</copyright-year><copyright-holder>Translational Lung Cancer Research.</copyright-holder><license><ali:license_ref specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref><license-p><italic toggle="yes">Open Access Statement:</italic> This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">https://creativecommons.org/licenses/by-nc-nd/4.0</ext-link>.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="tlcr-13-01-163.pdf"/><abstract><sec><title>Background and Objective</title><p>The role of biological sex is seldom considered in characterizing lung cancer, the deadliest cancer in both the United States and the world. Lung cancer has traditionally been regarded as a male disease; as such, research in female-specific phenomena is frequently conflicting or absent. Currently, disparities in lung cancer incidence are primarily driven by females, especially non-smokers and those of younger age. This narrative review provides insight into sex-specific characteristics of lung cancer, highlighting risk factors, diagnosis patterns, carcinogenesis, and treatment outcomes in females.</p></sec><sec><title>Methods</title><p>The PubMed database was searched on July 26, 2023 to identify research published between 2013 and 2023 in English. Sixty-three articles were considered relevant, and their full texts and citations were studied to compile information for this narrative review.</p></sec><sec><title>Key Content and Findings</title><p>Exposure-related risk factors, including personal tobacco use, are thought to impact female lung cancer risk more profoundly. However, studies on occupational exposures are underpowered to conclude risk in females. Data characterizing the effect of endogenous and exogenous hormonal exposures on female lung cancer risk remain two-sided. Screening guidelines are tailored to white males, exacerbating sex and race disparities. The effect of biological sex on carcinogenesis and the immune system response to cancer is not fully understood, though the female immune system clearly reacts more aggressively to lung cancer. In early-stage disease, females have greater survival in the perioperative setting and during follow-up of several years, attributed to favorable histopathology and healthier baseline status. Sex-specific response to systemic treatment continues to be optimized as lack of standardization in randomized trials makes interpreting results difficult when aggregated.</p></sec><sec><title>Conclusions</title><p>Biological sex plays a critical role in non-small cell lung cancer (NSCLC), though further study is needed to depict the complex web of factors that affect lung cancer risk, development, and outcomes. Female underrepresentation in studies has contributed to this lack of understanding. As these disparities are eliminated, we can move towards more effective treatment for both sexes in this pervasive yet deadly disease.</p></sec></abstract><kwd-group kwd-group-type="author"><title>Keywords: </title><kwd>Lung cancer</kwd><kwd>non-small cell lung cancer (NSCLC)</kwd><kwd>female</kwd><kwd>sex</kwd><kwd>sex difference</kwd></kwd-group><funding-group><award-group><funding-source id="sp1">the Department of Thoracic Surgery at Roswell Park Comprehensive Cancer Center and the University of Tennessee Graduate School of Medicine</funding-source></award-group></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro"><title>Introduction</title><p>Lung cancer is the leading cause of cancer death both in the United States and worldwide. In the United States, it has been the deadliest cancer for males since the 1950s and exceeded breast cancer as the deadliest for females in 1987 (<xref rid="r1" ref-type="bibr">1</xref>). In 2020, lung cancer caused 1,800,000 deaths worldwide, almost double the mortality of colorectal cancer, which is the second most deadly (<xref rid="r2" ref-type="bibr">2</xref>,<xref rid="r3" ref-type="bibr">3</xref>). Fortunately, lung cancer mortality in the United States has decreased annually since 2000. The Centers for Disease Control and Prevention reports the mortality rate of lung cancer was 55.8 per 100,000 people in 2000 but has now decreased to 33.4 per 100,000 people as of 2019, the most recent year for which reliable data are available (<xref rid="r4" ref-type="bibr">4</xref>). Likewise, the incidence of lung cancer has declined from 70.2 to 54.3 per 100,000 people, though the actual number of new lung cancers has generally increased over that period due to a growing population (<xref rid="r4" ref-type="bibr">4</xref>). Noticeably fewer new cases were reported in 2020, thought to be tempered by the unprecedented impact of the coronavirus disease 2019 (COVID-19) pandemic on health services and recommended screening practices (<xref rid="r4" ref-type="bibr">4</xref>). In recent years, lung cancer incidence has been 27% higher among males compared to females (<xref rid="r5" ref-type="bibr">5</xref>), though both incidence and mortality are declining more rapidly in males than females. These trends are generally attributed to differences in gendered smoking patterns (<xref rid="r5" ref-type="bibr">5</xref>).</p><p>This disease has two broad categories: small cell lung cancer and, conversely, non-small cell lung cancer (NSCLC). NSCLC is overwhelmingly more common with approximately 85% of new cases in the United States. Its incidence peaks at ages 80 to 84 in males compared to 75 to 79 in females (<xref rid="r5" ref-type="bibr">5</xref>). NSCLC is further divided into adenocarcinoma, squamous cell carcinoma, and large cell carcinoma (<xref rid="r6" ref-type="bibr">6</xref>,<xref rid="r7" ref-type="bibr">7</xref>). While tobacco use is widely known as the principal risk factor for lung cancer, these histologic varieties differ in &#8220;strength of the association&#8221; (<xref rid="r6" ref-type="bibr">6</xref>) with smoking. Importantly, disparities in lung cancer incidence largely depend on increasing rates of adenocarcinoma driven by young females and never smokers (<xref rid="r8" ref-type="bibr">8</xref>) yet understanding of this demographic shift is sorely needed. Consensus on lung cancer risk from non-tobacco exposures, the influence of sex-specific hormones, and the sex-based immune response to carcinogenesis are ill-defined in the literature. This narrative review aims to portray how biological sex affects NSCLC&#8212;its development, diagnosis, and treatment outcomes. We present this article in accordance with the Narrative Review reporting checklist (available at <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://tlcr.amegroups.com/article/view/10.21037/tlcr-23-744/rc" ext-link-type="uri">https://tlcr.amegroups.com/article/view/10.21037/tlcr-23-744/rc</ext-link>).</p></sec><sec sec-type="methods"><title>Methods</title><p>The PubMed literature database of the United States National Library of Medicine was used to identify previously published full-text research articles published in English from 2013 to 2023. All study designs and systematic and narrative reviews were included. A database search was performed on July 26, 2023, written as follows: ((gender[Title]) OR (sex[Title])) AND (lung cancer[Title]). The primary author reviewed the titles and abstracts of the 196 articles delivered. Articles of poor reliability or those that examined especially geographically-specific lung cancer trends were excluded. The authors considered sixty-two publications germane to the themes of this review and their full texts, including references, were studied in detail. Additional articles retrieved from references were included for completeness. The search strategy is summarized in <xref rid="t1" ref-type="table"><italic toggle="yes">Table 1</italic></xref> and included articles are identified explicitly in <xref rid="t2" ref-type="table"><italic toggle="yes">Table 2</italic></xref>.</p><table-wrap position="float" id="t1" orientation="portrait"><label>Table 1</label><caption><title>The search strategy summary</title></caption><table frame="hsides" rules="groups"><col width="29.22%" span="1"/><col width="70.78%" span="1"/><thead><tr><th valign="middle" align="left" scope="col" rowspan="1" colspan="1">Items</th><th valign="middle" align="left" scope="col" rowspan="1" colspan="1">Specification</th></tr></thead><tbody><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Date of search</td><td valign="top" align="left" rowspan="1" colspan="1">July 26, 2023</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Databases and other sources searched</td><td valign="top" align="left" rowspan="1" colspan="1">PubMed</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Search terms used</td><td valign="top" align="left" rowspan="1" colspan="1">((gender[Title]) OR (sex[Title])) AND (lung cancer[Title])</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Timeframe</td><td valign="top" align="left" rowspan="1" colspan="1">2013 to 2023</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Inclusion and exclusion criteria</td><td valign="top" align="left" rowspan="1" colspan="1">Only full text articles in English included. Articles that examined geographically-specific lung cancer incidence were excluded</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Selection process</td><td valign="top" align="left" rowspan="1" colspan="1">K.G. conducted selection independently, and the authors discussed the scientific and clinical value of controversial articles to reach an agreement</td></tr></tbody></table></table-wrap><table-wrap position="float" id="t2" orientation="portrait"><label>Table 2</label><caption><title>Articles selected for inclusion (first author, PubMed ID)</title></caption><table frame="hsides" rules="groups"><col width="20.97%" span="1"/><col width="18.19%" span="1"/><col width="16.98%" span="1"/><col width="22.99%" span="1"/><col width="20.87%" span="1"/><thead><tr><th valign="middle" align="left" scope="col" rowspan="1" colspan="1">Risk factors</th><th valign="middle" align="center" scope="col" rowspan="1" colspan="1">Screening and diagnosis</th><th valign="middle" align="center" scope="col" rowspan="1" colspan="1">Carcinogenesis</th><th valign="middle" align="center" scope="col" rowspan="1" colspan="1">Outcomes</th><th valign="middle" align="center" scope="col" rowspan="1" colspan="1">ICI efficacy evaluated in recent meta-analyses</th></tr></thead><tbody><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Baiu I, 34277072</td><td valign="top" align="center" rowspan="1" colspan="1">Araghi M, 34282033</td><td valign="top" align="center" rowspan="1" colspan="1">Caetano MS, 30389925</td><td valign="top" align="center" rowspan="1" colspan="1">Al Omari O, 36476451</td><td valign="top" align="center" rowspan="1" colspan="1">Conforti F, 31106827</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Betansedi CO, 29508431</td><td valign="top" align="center" rowspan="1" colspan="1">Pinsky PF, 33545164</td><td valign="top" align="center" rowspan="1" colspan="1">Dubois C, 30444717</td><td valign="top" align="center" rowspan="1" colspan="1">Baum P, 35220299</td><td valign="top" align="center" rowspan="1" colspan="1">Liang J, 36128737</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Boice JD, 30614747</td><td valign="top" align="center" rowspan="1" colspan="1">Ragavan M, 35022255</td><td valign="top" align="center" rowspan="1" colspan="1">Freudenstein D, 32545367</td><td valign="top" align="center" rowspan="1" colspan="1">Baum P, 35738973</td><td valign="top" align="center" rowspan="1" colspan="1">Madala S, 35400597</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Bugge A, 27846762</td><td valign="top" align="center" rowspan="1" colspan="1">Ruano-Ravina A, 34858780</td><td valign="top" align="center" rowspan="1" colspan="1">Gu T, 25320584</td><td valign="top" align="center" rowspan="1" colspan="1">Bugge A, 27846762</td><td valign="top" align="center" rowspan="1" colspan="1">Takada K, 35999618</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Cheng TD, 29346580</td><td valign="top" align="center" rowspan="1" colspan="1">Smeltzer MP, 36208717</td><td valign="top" align="center" rowspan="1" colspan="1">Mederos N, 33148544</td><td valign="top" align="center" rowspan="1" colspan="1">Conforti F, 31106827</td><td valign="top" align="center" rowspan="1" colspan="1">Wang C, 30972745</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Fuentes N, 34080912</td><td valign="top" align="center" rowspan="1" colspan="1">Tolwin Y, 32532368</td><td valign="top" align="center" rowspan="1" colspan="1">Nabi H, 29688493</td><td valign="top" align="center" rowspan="1" colspan="1">Conforti F, 34455288</td><td valign="top" align="center" rowspan="1" colspan="1">Xue C, 34513654</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Hansen MS, 29087432</td><td valign="top" align="center" rowspan="1" colspan="1">Warner ET, 31054908</td><td valign="top" align="center" rowspan="1" colspan="1">P&#233;rez-D&#237;ez I, 33526761</td><td valign="top" align="center" rowspan="1" colspan="1">Deng HY, 33899137</td><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Lin PC, 30225650</td><td valign="top" align="center" rowspan="1" colspan="1">Yoshida Y, 26366891</td><td valign="top" align="center" rowspan="1" colspan="1">Raskin J, 35884463</td><td valign="top" align="center" rowspan="1" colspan="1">Duma N, 31036771</td><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">May L, 37370722</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">Siegfried JM, 34927202</td><td valign="top" align="center" rowspan="1" colspan="1">Huang Y, 35693273</td><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Mederos N, 33148544</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">Skjefstad K, 25668612</td><td valign="top" align="center" rowspan="1" colspan="1">Isla, D 27885542</td><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Meza R, 25822850</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">Stapelfeld C, 28743530</td><td valign="top" align="center" rowspan="1" colspan="1">McGuire AL, 35448189</td><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Pinheiro PS, 36334356</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">Vaval&#224; T, 34769372</td><td valign="top" align="center" rowspan="1" colspan="1">Pinto JA, 29682332</td><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Ragavan M, 35022255</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">Xu L, 35577039</td><td valign="top" align="center" rowspan="1" colspan="1">Radkiewicz C, 31247015</td><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Ragavan MV, 32774466</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">Ragavan M, 35022255</td><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Siegfried JM, 34927202</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">Raskin J, 35884463</td><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Stapelfeld C, 28743530</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">Sachs E, 33217414</td><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Stapelfeld C, 31583690</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">Ten Haaf K, 25312998</td><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Wijesinghe AI, 37271799</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">Tong BC, 24726742</td><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Yu Y, 25064415</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">Vaval&#224; T, 34769372</td><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Zeng H, 34112140</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">Wainer Z, 27625078</td><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">Wainer Z, 30206043</td><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">Watanabe K, 29582626</td><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">Xiao J, 32984005</td><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">Yoshida Y, 26366891</td><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">Yu XQ, 35124253</td><td valign="top" align="left" rowspan="1" colspan="1"/></tr></tbody></table><table-wrap-foot><p>ICI, immune checkpoint inhibitor.</p></table-wrap-foot></table-wrap></sec><sec sec-type="other1"><title>Risk factors</title><sec><title>Smoking and chronic obstructive pulmonary disease (COPD)</title><p>Far and away, the most important risk factor for developing lung cancer is tobacco use. The fact that 85% of lung cancer deaths worldwide can be attributed to smoking (<xref rid="r2" ref-type="bibr">2</xref>,<xref rid="r9" ref-type="bibr">9</xref>) highlights the preventable nature of most lung cancer diagnoses and reinforces that tobacco smoking is the most influential modifiable risk factor for lung cancer (<xref rid="r10" ref-type="bibr">10</xref>). Models developed to project smoking patterns and lung cancer mortality in the United States anticipate that sex disparities in lung cancer rates will dissipate by the mid-2040s and that smoking prevalence will drop to only 7.5% by 2065, though this percentage still corresponds to some 50,000 lung cancer deaths (<xref rid="r11" ref-type="bibr">11</xref>).</p><p>Differences in gendered smoking habits have contributed to the changing demographics of lung cancer (<xref rid="r8" ref-type="bibr">8</xref>). In the 1960s, male cigarette use began to decrease, and the incidence of squamous cell carcinoma accordingly declined. It is thought that changes in cigarette filtration systems, which primarily occurred in the late 1960s and 1970s, allowed smaller particles to travel more distally within the lungs thus contributing to the upward trend of adenocarcinoma (<xref rid="r12" ref-type="bibr">12</xref>-<xref rid="r14" ref-type="bibr">14</xref>). Indeed, adenocarcinoma surpassed squamous cell carcinoma as the most frequently diagnosed lung cancer in males around 1994 (<xref rid="r6" ref-type="bibr">6</xref>). In contrast, women began smoking in higher proportions decades after men, the smoking rate began to decline after that of men, and smoking cessation continues to take place at a slower pace in women (<xref rid="r8" ref-type="bibr">8</xref>). Adenocarcinoma now accounts for more than 50% of lung cancer cases in females compared to approximately 30% 50 years ago (<xref rid="r6" ref-type="bibr">6</xref>).</p><p>Data disagrees on which is the more important prognostic factor in developing lung cancer&#8212;smoking status or smoking intensity. Some studies purport that smoking status trumps intensity as higher pack-years in males compared to females did not affect mortality rates between the two sexes (<xref rid="r15" ref-type="bibr">15</xref>). Conversely, when smoking amount was measured as a continuous variable in another study, female smokers had a progressively greater risk of lung cancer as pack-years of use, number of daily cigarettes, and usage duration increased as compared to males (<xref rid="r16" ref-type="bibr">16</xref>).</p><p>In the past, studies have generally recognized that females are more sensitive to cigarette smoke (<xref rid="r14" ref-type="bibr">14</xref>,<xref rid="r17" ref-type="bibr">17</xref>-<xref rid="r19" ref-type="bibr">19</xref>). Of those diagnosed with COPD or lung cancer, studies show that females generally have 20&#8211;25% less pack-years of tobacco use (<xref rid="r20" ref-type="bibr">20</xref>). Similarly, with equivalent amounts of smoking history, females are more likely to develop both adenocarcinoma and squamous cell carcinoma compared to males (<xref rid="r18" ref-type="bibr">18</xref>). Conversely, a meta-analysis published in 2014 with more than 400,000 individuals from 47 studies found a 1.61 relative risk ratio [95% confidence interval (CI): 1.37&#8211;1.89] of developing lung cancer for male to female smokers (<xref rid="r21" ref-type="bibr">21</xref>). Thus, debate remains about which sex is more susceptible to the negative effects from smoking.</p><p>COPD is also a risk factor for lung cancer. Bronchial hyperresponsiveness, airway obstruction that is often a component of asthma and COPD, is present in 87% of female smokers with mild to moderate COPD <italic toggle="yes">vs.</italic> 63% of male smokers (<xref rid="r22" ref-type="bibr">22</xref>). In females, airway obstruction presents earlier and with greater bronchial wall thickening as compared to males (<xref rid="r20" ref-type="bibr">20</xref>). Cigarette use is the single most important risk factor in exhibiting bronchial hyperresponsiveness in females. In contrast, atopy and asthma are the foremost risk factors for males. Females are twice as likely as males to develop lung cancer with comparable decreases in forced expiratory volume in one second, even when adjusted for smoking history (<xref rid="r22" ref-type="bibr">22</xref>). Mathematical quantification of the effect of cigarette smoke on lung parenchyma using a novel smoking-emphysema index, determined by low-attenuation area volume percentage on three-dimensional computed tomography scan divided by pack-years of smoking, demonstrated a greater volume of emphysematous change in male lungs overall. Nonetheless, females were found to have greater low-attenuation area volume percentage per cigarette smoked (<xref rid="r23" ref-type="bibr">23</xref>).</p></sec><sec><title>Exposure-related risk factors in females</title><p>Exposure to second-hand smoke, more commonly experienced by women, increases the risk of lung cancer. An observational study of non-smokers with lung cancer found 69% of females experienced environmental tobacco smoke exposure, compared to only 17% of males. Interestingly, males in this study reported exposure only at work, while females experienced exposure at home and work (<xref rid="r24" ref-type="bibr">24</xref>). Known risk factors such as asbestos and radon have been particularly poorly studied in women, though women spend more time in the home and consequently have greater exposure to indoor pollution including radon and tobacco smoke residues that persist on indoor surfaces, termed thirdhand smoke (<xref rid="r14" ref-type="bibr">14</xref>,<xref rid="r25" ref-type="bibr">25</xref>). A recent meta-analysis found cooking factors, including fume and coal smoke exposure, conferred the highest lung cancer risk to non-smoking Asian women [odds ratio (OR), 2.15; 95% CI: 1.87&#8211;2.47] among pooled risk categories of personal and family history, environmental tobacco exposure, diet, and reproductive factors (<xref rid="r26" ref-type="bibr">26</xref>). Female chefs exposed more intensely and for more years to cooking oil fumes, which contain known carcinogens, had a significantly higher risk of lung adenocarcinoma compared to male chefs and those less often exposed to cooking oil fumes due to specific cooking practices (<xref rid="r27" ref-type="bibr">27</xref>). Research on occupational cancer epidemiology shows that in male-dominated fields like extractive industry, construction, and agriculture, exposure studies are more likely to have a greater than 3.5 ratio of male to female participants (P&lt;0.001), therefore making it difficult to draw conclusions about male <italic toggle="yes">vs.</italic> female occupational exposure risk (<xref rid="r28" ref-type="bibr">28</xref>). Differences in lung cancer risk secondary to radiation exposure remain ill-defined, partially because studies have relatively low female participants (<xref rid="r29" ref-type="bibr">29</xref>). However, as the incidence of breast cancer in younger females increases, concern over early exposure to radiation is warranted (<xref rid="r30" ref-type="bibr">30</xref>).</p></sec><sec><title>Hormonally based risk</title><p>Many doubts remain about one category of lung cancer patient: the female never-smoker. The label &#8220;never smoker&#8221; refers to someone who has smoked less than 100 cigarettes in their lifetime (<xref rid="r7" ref-type="bibr">7</xref>). Alarmingly, deaths from lung cancer in never smokers would rank as the seventh most common cause of cancer death worldwide (<xref rid="r7" ref-type="bibr">7</xref>,<xref rid="r10" ref-type="bibr">10</xref>). Female never smokers are more likely to develop lung cancer than their male counterparts (<xref rid="r1" ref-type="bibr">1</xref>,<xref rid="r8" ref-type="bibr">8</xref>,<xref rid="r17" ref-type="bibr">17</xref>), which holds true across ethnicities (<xref rid="r31" ref-type="bibr">31</xref>). The rate of lung cancer diagnosis in never-smoking females is characterized as 14.4 to 20.8 per 100,000 person-years <italic toggle="yes">vs.</italic> 4.8 to 13.7 per 100,000 person-years for males (<xref rid="r25" ref-type="bibr">25</xref>).</p><p>Within this demographic, the effect of hormonal exposures has been considered a probable contributor (<xref rid="r9" ref-type="bibr">9</xref>,<xref rid="r32" ref-type="bibr">32</xref>). Of reproductive factors examined including parity, age at first birth, age at menopause, and exogenous hormone use, only bilateral oophorectomy significantly increased lung cancer risk in never smokers [hazard ratio (HR), 1.47; 95% CI: 1.00&#8211;2.16] in an observational study of almost 162,000 women from the United States (<xref rid="r33" ref-type="bibr">33</xref>). In a study that closely followed over 71,000 never-smoking Chinese females, older age at menopause, longer reproductive period, increased parity, and history of intrauterine device usage significantly decreased lung cancer risk (<xref rid="r32" ref-type="bibr">32</xref>). On the whole, though, data regarding lung cancer risk secondary to endogenous estrogen exposure is inconsistent. Additionally, the role of endogenous <italic toggle="yes">vs.</italic> exogenous estrogen exposure is a secondary query that requires further investigation (<xref rid="r30" ref-type="bibr">30</xref>). A meta-analysis of sex steroids and female lung cancer risk found that the summative effect of higher levels of both endogenous and exogenous hormone exposure reduced lung cancer risk in females by 10%. This result was consistent in subgroup analysis of both Asian (OR, 0.90; 95% CI: 0.84&#8211;0.99) and Western (OR, 0.90; 95% CI: 0.84&#8211;0.96) females, though for distinct underlying causes of exposure (<xref rid="r34" ref-type="bibr">34</xref>). However, there is evidence suggesting estrogen exposure via hormone replacement therapy may in fact increase lung cancer risk in women (<xref rid="r8" ref-type="bibr">8</xref>,<xref rid="r30" ref-type="bibr">30</xref>,<xref rid="r35" ref-type="bibr">35</xref>,<xref rid="r36" ref-type="bibr">36</xref>).</p></sec></sec><sec sec-type="other2"><title>Screening and diagnosis</title><p>The National Lung Screening Trial was a large, multicenter, randomized-controlled trial that found a 20% reduction in mortality for heavy smokers screened annually with low-dose computed tomography (LDCT) <italic toggle="yes">vs.</italic> chest X-ray (<xref rid="r37" ref-type="bibr">37</xref>). In consideration of these and other results, the United States Preventative Services Task Force currently recommends annual screening with LDCT for adults aged 50 to 80 years with a 20-pack-year tobacco use history who continue to smoke or have quit within the last 15 years (<xref rid="r38" ref-type="bibr">38</xref>). Guidelines were expanded in 2021 in part to reach high-risk groups, particularly women and minorities (<xref rid="r30" ref-type="bibr">30</xref>,<xref rid="r39" ref-type="bibr">39</xref>). Similarly, the National Comprehensive Cancer Network recommends patients aged greater than 50 years with at least 20 years of smoking history to participate in shared decision-making with their healthcare provider regarding lung cancer screening with LDCT (<xref rid="r40" ref-type="bibr">40</xref>). Regrettably, screening uptake remains low despite expanded criteria, and many diagnosed with lung cancer do not meet eligibility for screening (<xref rid="r39" ref-type="bibr">39</xref>,<xref rid="r41" ref-type="bibr">41</xref>).</p><p>Screening recommendations are largely based on the lung cancer risk of white males, and because females typically develop lung cancer at a younger age and with less smoking exposure, they are less likely to qualify for screening (<xref rid="r39" ref-type="bibr">39</xref>). By examining a &#8220;natural experiment&#8221; in which patients with a suspicious lung nodule were assessed for lung cancer screening eligibility, Smeltzer <italic toggle="yes">et al.</italic> proved that expanding eligibility criteria to include patients with 10 pack-years&#8217; tobacco use and patients who quit within the last 25 years would reach a new population comprised of 57% females (P=0.0476), reversing some of the sex disparity in current screening recommendations (<xref rid="r39" ref-type="bibr">39</xref>). In a nationwide survey, females were less likely than males to report having discussed lung cancer screening with their healthcare provider regardless of smoking status, though these results did not reach statistical significance, and 32% less likely to have heard of LDCT (OR, 0.68; 95% CI: 0.47&#8211;0.99). Over the survey period of 2012&#8211;2017, there was no evidence of increased discussion between provider and patient regarding screening recommendations (<xref rid="r42" ref-type="bibr">42</xref>). Moreover, a study in Spain found no clinically relevant differences in symptoms at diagnosis between patients of either sex or variable smoking status (<xref rid="r43" ref-type="bibr">43</xref>), highlighting that healthcare providers must remain vigilant when determining patients who may benefit from lung cancer screening.</p><p>Review of the Surveillance, Epidemiology, and End Results (SEER) database reveals that a greater proportion of males are diagnosed with stage III and IV lung cancer compared to females (75.6% <italic toggle="yes">vs.</italic> 72%, P&lt;0.0001) (<xref rid="r44" ref-type="bibr">44</xref>). This finding is replicated in other high-income countries including Australia, Canada, Ireland, Norway, and the United Kingdom (<xref rid="r45" ref-type="bibr">45</xref>). Predictably, when SEER data were examined at the county level, the percentage difference in late-stage diagnosis for males and females diminished as the proportion of female smokers increased. This trend remained consistent when examining lung cancers more associated with smoking (squamous and small cell carcinomas), perhaps suggesting that smokers of either sex are less likely to seek medical opinion when faced with symptoms concerning for lung cancer (<xref rid="r44" ref-type="bibr">44</xref>).</p></sec><sec sec-type="other3"><title>Carcinogenesis and the resultant immune response</title><sec><title>Smoking, sex steroids, and carcinogenesis</title><p>Cigarette smoking has been demonstrated to affect the immune system by reducing neutrophil, antigen-presenting cell, and global T-cell activity (<xref rid="r46" ref-type="bibr">46</xref>). On the whole, animal studies generally indicate that when exposed to cigarette smoke and its metabolites, females mount a robust inflammatory response leading to increased oxidative stress in the environment, eventually making cells more susceptible to genetic mutation and malignancy (<xref rid="r22" ref-type="bibr">22</xref>). Further, female smokers have higher levels of DNA adducts in peripheral blood mononuclear cells as compared to males (<xref rid="r20" ref-type="bibr">20</xref>), and 10&#8211;15% less capacity for DNA repair (<xref rid="r14" ref-type="bibr">14</xref>,<xref rid="r22" ref-type="bibr">22</xref>). Compared to male smokers, female smokers have increased cytochrome P450 (CYP) enzyme expression in their lungs (<xref rid="r22" ref-type="bibr">22</xref>). Tobacco smoke itself induces expression of CYP1B1, which then metabolizes estrogen and procarcinogens to their toxic state (<xref rid="r47" ref-type="bibr">47</xref>). N-nitrosamines and polycyclic aromatic hydrocarbons, two harmful tobacco-related substances, are primarily catalyzed by CYP to become carcinogenic (<xref rid="r22" ref-type="bibr">22</xref>,<xref rid="r48" ref-type="bibr">48</xref>). For example, an N-nitrosamine known as nicotine-derived nitrosamine ketone (NNK) is normally broken down via carbonyl reduction; yet without carbonyl reduction, NNK is hydroxylated by CYP and forms DNA adducts. A study which investigated the inhibitory effects of sex hormones on this process showed that progesterone and its synthetic analog were the most powerful inhibitors of safe NNK metabolization (<xref rid="r36" ref-type="bibr">36</xref>).</p><p>Various studies have attempted to utilize sex steroids, including estrogen receptor-alpha and beta, as a biomarker or determine their prognostic value in lung cancer (<xref rid="r9" ref-type="bibr">9</xref>,<xref rid="r14" ref-type="bibr">14</xref>,<xref rid="r49" ref-type="bibr">49</xref>-<xref rid="r52" ref-type="bibr">52</xref>). In order to influence gene expression, estrogen can bind with its receptor and function as a transcription factor or translocate across the cell membrane to induce more immediate events such as ion channel regulation, activation of protein kinase, or formation of second messengers (<xref rid="r9" ref-type="bibr">9</xref>,<xref rid="r53" ref-type="bibr">53</xref>). Estrogen receptor-beta, which is found more diffusely throughout the body, is highly expressed in bronchial epithelial cells and pneumocytes and contributes to maintenance of extracellular matrix of the lung (<xref rid="r9" ref-type="bibr">9</xref>). <italic toggle="yes">KRT16</italic>, an essential gene in estrogen receptor signaling, was found to be significantly overexpressed in the tumor tissue of female non-smoking lung adenocarcinoma patients compared to that of males, and likelihood of death in females with high <italic toggle="yes">KRT16</italic> expression was nearly double compared to males. Bearing in mind these results, estrogen blockade signaling may be an effective option for targeted therapy in non-smoking patients (<xref rid="r54" ref-type="bibr">54</xref>). A prospectively enrolled case-case study on hormone receptor expression demonstrated that female sex was associated with lower cytoplasmic estrogen receptor-alpha and nuclear estrogen receptor-beta expression than male sex when adjusted for age, race, and smoking. Additionally, ever-smokers also had lower cytoplasmic estrogen receptor-beta expression. The authors concluded their results supported the &#8220;estrogen hypothesis&#8221;&#8212;that is, estrogens play a role in lung carcinogenesis (<xref rid="r17" ref-type="bibr">17</xref>). However, concerns have been raised about the application of these findings, given the study did not consider obesity in its analysis, which is known to modulate estrogen and possibly estrogen receptors (<xref rid="r55" ref-type="bibr">55</xref>).</p><p>Studies with murine models likewise present conflicting data. Exposure to estradiol resulted in two-fold larger lung tumors, as well as increased angiogenesis and lymphangiogenesis, in immunocompetent female mice compared to male mice. This paradigm persisted in ovariectomized mice, which displayed the least tumor development, while ovariectomized mice treated with estradiol supplementation displayed moderate tumor growth. In contrast, castration of male mice did not affect tumor size, nor did castration with subsequent estradiol supplementation (<xref rid="r56" ref-type="bibr">56</xref>). Conversely, another study showed that when estrogen signaling was inhibited via tamoxifen in female mice, <italic toggle="yes">KRAS</italic> mutant lung cancer development was augmented (<xref rid="r57" ref-type="bibr">57</xref>). Sex steroids seem to play a role in the relationship between tobacco smoke and carcinogenesis, thus contributing to sex-based differences in lung cancer development, though this relationship remains to be clearly described.</p></sec><sec><title>Females have a stronger immune system</title><p>It is well known that females have a more robust immune system, which is borne out in higher incidence of autoimmune disease and lower prevalence of infection or cancer compared to males (<xref rid="r46" ref-type="bibr">46</xref>,<xref rid="r58" ref-type="bibr">58</xref>). Many genes that participate in the regulation of immune response are located on the X chromosome (<xref rid="r46" ref-type="bibr">46</xref>,<xref rid="r58" ref-type="bibr">58</xref>,<xref rid="r59" ref-type="bibr">59</xref>). Females have enhanced function of both innate and adaptive immunity (<xref rid="r46" ref-type="bibr">46</xref>,<xref rid="r58" ref-type="bibr">58</xref>-<xref rid="r62" ref-type="bibr">62</xref>), including higher phagocytic capacity of both neutrophils and macrophages, greater antibody response with elevated basal immunoglobulin levels and B-cell numbers, and increased CD4<sup>+</sup> T-cell count, and T-cell proliferation and activation (<xref rid="r46" ref-type="bibr">46</xref>,<xref rid="r58" ref-type="bibr">58</xref>). Additionally, estrogens alter the milieu of inflammatory cytokines produced by macrophages and neutrophils, which may influence overall less cancer risk seen in females (<xref rid="r46" ref-type="bibr">46</xref>).</p></sec><sec><title>Immune response differences in adenocarcinoma according to sex</title><p>Novel studies reveal baseline differences in male and female immune responses to lung adenocarcinoma that may contribute to sex disparities in tumor burden and disease outcome (<xref rid="r13" ref-type="bibr">13</xref>). Female adenocarcinoma patients tend to have a more robust anti-cancer immune response, specifically a higher proportion of immune infiltrate, than their male counterparts, which may contribute to worse prognosis seen in males (<xref rid="r13" ref-type="bibr">13</xref>,<xref rid="r63" ref-type="bibr">63</xref>). In fact, lymphocytic infiltration with CD3<sup>+</sup> and CD8<sup>+</sup> cells has been linked to superior outcomes in multiple tumors (<xref rid="r64" ref-type="bibr">64</xref>). In &#8220;The Immune Landscape of Cancer&#8221;, Thorsson <italic toggle="yes">et al.</italic> described a framework for examining &#8220;immune signature&#8221; in various cancers, which includes six subtypes: wound healing, interferon (INF)-gamma dominant, inflammatory, lymphocyte depleted, immunologically quiet, and transforming growth factor (TGF)-beta dominant (<xref rid="r65" ref-type="bibr">65</xref>). In female lung adenocarcinoma, INF-gamma, lymphocytic infiltration, and M1 macrophage enrichment were noted. Evaluation of immune-related gene expression revealed predominance of antigen processing and presentation pathways. In contrast, male tumors trended towards M2 macrophage enrichment (<xref rid="r65" ref-type="bibr">65</xref>). Those with wild type-<italic toggle="yes">TP53</italic> tumors and high expression of these immune-related genes demonstrated a statistically significant survival benefit compared to the wild type-<italic toggle="yes">TP53</italic>, low expression group, and mutant <italic toggle="yes">TP53</italic> groups with both high and low expression of these genes, regardless of sex, highlighting the clinical significance of this work (<xref rid="r13" ref-type="bibr">13</xref>).</p></sec></sec><sec sec-type="other4"><title>Outcomes</title><p>Understanding of lung cancer in females generally concludes favorable prognosis compared to male counterparts. From 1999 to 2019 in the United States, females with lung cancer consistently had decreased age-standardized mortality rates compared to males (<xref rid="r66" ref-type="bibr">66</xref>). In fact, when controlling for age, smoking history, stage at diagnosis, and histology, females demonstrate superior survival rates (<xref rid="r30" ref-type="bibr">30</xref>,<xref rid="r67" ref-type="bibr">67</xref>,<xref rid="r68" ref-type="bibr">68</xref>). SEER data reveals that males have significantly worse survival than females across all stages defined in the 8th edition of the tumor, node, metastasis staging system, with the greatest disparity noted in early stage disease at both 1 and 5 years of follow-up (<xref rid="r69" ref-type="bibr">69</xref>).</p><p>Compared to males, females are more likely to be diagnosed at earlier stages, be never-smokers, and have adenocarcinoma histology (<xref rid="r70" ref-type="bibr">70</xref>,<xref rid="r71" ref-type="bibr">71</xref>). The period during which a patient is asymptomatic from disease yet lung cancer is detectable on imaging was found to be 4.48 years for males compared to 6.01 years for females (<xref rid="r72" ref-type="bibr">72</xref>). This is indicative of the fact that females are more likely to be diagnosed with adenocarcinoma, characteristically slower-growing, thus offering greater opportunity for early-stage diagnosis. Furthermore, most of the excess death risk in males diagnosed with lung cancer can be attributed to known prognostic factors, including patient characteristics, demographic and lifestyle data, and tumor- and treatment-related factors (<xref rid="r73" ref-type="bibr">73</xref>). When adjusting for these predictive factors, Yu <italic toggle="yes">et al.</italic> were able to show reduction in risk of death from HR 1.33 to 1.06 (95% CI: 0.96&#8211;1.18; P=0.26), achieving a non-significant difference in death risk between males and females. Approximately 50% of the excess risk of death came from treatment-related factors, specifically receiving surgery, systemic therapy, or radiation within 6 months of diagnosis (<xref rid="r73" ref-type="bibr">73</xref>). This review will concentrate on sex-based differences in outcomes of surgery, the favored management of early disease, and contemporary systemic treatments.</p><sec><title>Surgery for early-stage lung cancer</title><p>The primary treatment of stage I and II lung cancer is surgery with curative intent. Definitive radiation is considered if the patient is not a surgical candidate secondary to comorbidities or problematic tumor location. A previous meta-analysis of patients with inoperable NSCLC treated with radiation found that female gender was the sole demographic factor to confer an overall survival benefit (<xref rid="r74" ref-type="bibr">74</xref>). In contrast, a large retrospective study of patients who underwent stereotactic body radiation therapy found that unfavorable histology, increased body mass index, significant comorbidities, and radiation dosing were predictive of local treatment failure, but not sex (<xref rid="r75" ref-type="bibr">75</xref>).</p><p>Various studies of patients with early-stage NSCLC undergoing resection find superior outcomes for females in both overall and perioperative survival. A retrospective review of 735 NSCLC surgical resection cases from 1995 to 2010 at a single Japanese institution demonstrated that overall survival at 1, 3, and 5 years was significantly better for females. Subgroup analysis further revealed that female sex and adenocarcinoma histology were significant positive prognostic factors only in pathologic stages I and II (n=557). Female survival advantage was lost in late-stage disease; survival curves crossed at around 4 years of follow-up (<xref rid="r70" ref-type="bibr">70</xref>). Importantly, length-time bias could have contributed to the improved overall survival seen in females as they were more frequently diagnosed with screening or with incidental imaging (<xref rid="r70" ref-type="bibr">70</xref>). Similarly, male sex was found to be an independent negative prognostic factor (HR, 1.54; 95% CI: 1.10&#8211;2.16) for mortality at 5-year in an Australian cohort study performed between 2000 and 2009. As female patients were diagnosed with higher stage disease, their mortality risk increased at a faster pace compared to males. For example, stages III and IV conferred a HR 8.71 for female patients <italic toggle="yes">vs.</italic> 3.66 for male patients compared to the reference group which was comprised of patients diagnosed at Stage IA, meaning their tumors were less than three centimeters (<xref rid="r76" ref-type="bibr">76</xref>).</p><p>Even in studies with longer follow-up, survival advantage in females persists. A prospective cohort study of stage I and II NSCLC patients conducted in Norway from 2003 to 2013 determined 37.8% survival for females <italic toggle="yes">vs.</italic> 28.2% in males at 10 years of follow-up, though this difference did not reach statistical significance in the relatively small study population (n=692) (<xref rid="r15" ref-type="bibr">15</xref>). Females 66 years and older did have a statistically significant greater survival than males at 10 years (28.2% <italic toggle="yes">vs.</italic> 19.5%, P&lt;0.03). By the end of ongoing follow-up, that significance was lost (P=0.06), which was attributed to confounders such as pack-years of smoking, cancer stage, large cell carcinoma histology, and lobectomy (<xref rid="r15" ref-type="bibr">15</xref>). A nationwide observational cohort study of 6,536 patients who underwent pulmonary resection for lung cancer in Sweden from 2008 to 2017 found a lower risk of death in females compared to males with increasing absolute survival difference over 10 years of follow-up (<xref rid="r77" ref-type="bibr">77</xref>). When the cohort was divided by pathologic stage, histology, and age, except for those younger than 60 years, improved survival for women was maintained regardless of differences in patient characteristics such as comorbidities, frailty, and socioeconomic status. The advantage was conferred in both adenocarcinoma and squamous cell carcinoma, though to a lesser extent with the latter (<xref rid="r77" ref-type="bibr">77</xref>). These studies beg the question: why do younger females with early-stage lung cancer have comparatively less survival advantage than their elders?</p><p>Regarding perioperative survival, females undergoing lung resection are generally younger and have fewer comorbidities (<xref rid="r78" ref-type="bibr">78</xref>,<xref rid="r79" ref-type="bibr">79</xref>). A retrospective review of a German discharge registry of almost 39,000 patients undergoing lung resection from 2014 to 2017 compared in-hospital mortality, complications, and comorbidities between the sexes. They found a difference in raw in-hospital mortality: 1.8% for females and 4.1% for males. Regardless of surgical approach, women had significantly fewer post-operative complications, including prolonged ventilation, pneumonia, tracheotomy, empyema, and sepsis. Women were significantly less likely to have hypertension, chronic renal failure, diabetes mellitus, and COPD, which continued to be true after stratifying for open <italic toggle="yes">vs.</italic> minimally invasive surgery. They were also significantly more likely to be referred, compared to males, who were more frequently admitted in an emergent fashion or transferred from another hospital. In multivariable regression, in-hospital mortality advantage for females was maintained&#8212;they were 21% less likely to die in hospital following lung resection for cancer (OR, 0.79; 95% CI: 0.66&#8211;0.93; P&lt;0.005) (<xref rid="r78" ref-type="bibr">78</xref>). An analogous study performed in the United States reviewed more than 34,000 patients from the Society of Thoracic Surgeons General Thoracic Surgery Database undergoing resection for lung cancer between 2002 and 2010 similarly found females to have significantly less coronary artery disease, diabetes, and renal insufficiency. Combined in-hospital and 30-day mortality was found to be 1.5% in females and 3% in males (<xref rid="r79" ref-type="bibr">79</xref>).</p><p>It is imperative to recognize these studies were performed during years in which video-assisted thoracoscopic surgery (VATS) techniques were being adopted. In the Society of Thoracic Surgeons database, lobectomies via VATS increased by 10.4% between 2004 and 2006 (<xref rid="r80" ref-type="bibr">80</xref>). By 2013, surgeons in Japan self-reported performing 68.9% of lobectomies using VATS techniques (<xref rid="r81" ref-type="bibr">81</xref>). As this minimally invasive technique was being implemented, it is logical that surgeons may have chosen certain patients, such as those with smaller tumors or better functional status, to undergo a relatively unfamiliar VATS procedure. Years later, the data exists to show that VATS procedures reduce post-operative complications and improve long-term survival (<xref rid="r77" ref-type="bibr">77</xref>,<xref rid="r82" ref-type="bibr">82</xref>), which may have influenced superior survival outcomes following lung resection seen in females.</p><p>Studies have demonstrated sex disparities in surgery for early-stage lung cancer. A review of patients with stage I NSCLC who participated prospectively in the National Lung Screening Trial found that women were &#8220;less likely to undergo full resection&#8221; despite having surgery as often as men, though this was not statistically significant. The authors posited favorable pathology and patient preference may have influenced these decisions (<xref rid="r83" ref-type="bibr">83</xref>). An early comparison of limited resection <italic toggle="yes">vs.</italic> lobectomy for stage IA lung cancer showed that limited resection was performed in females more often (<xref rid="r84" ref-type="bibr">84</xref>), though we now have robust evidence that sublobar resection is non-inferior to lobectomy in patients with clinical stage IA peripheral NSCLC tumors less than two centimeters (<xref rid="r85" ref-type="bibr">85</xref>,<xref rid="r86" ref-type="bibr">86</xref>). What was previously considered a limited resection is now known to be a suitable choice in select patients. Further, propensity-matched patients with stage IA peripheral NSCLC were found to have no difference in the rate of lymph node metastases between the sexes, suggesting no justification for offering sex-dependent surgical resection (<xref rid="r87" ref-type="bibr">87</xref>).</p></sec><sec><title>Recurrence after surgical resection</title><p>When early-stage tumors are resected with curative intent, molecular testing with next-generation sequencing is not typically performed though up to 70% of these patients will ultimately have cancer recurrence (<xref rid="r88" ref-type="bibr">88</xref>). Following surgical resection with frequent surveillance, men more frequently recurred within the first year after surgery while peak recurrence in women occurred over a longer range of duration from 2 to 3 years following surgery (<xref rid="r71" ref-type="bibr">71</xref>). A recent propensity-matched cohort controlling for sex and smoking status of early- and late-stage NSCLC patients demonstrated no differences in the frequency of targetable mutations, thus making a case for routine sequencing of resected specimens to optimize systemic therapy for future recurrence, should it be needed (<xref rid="r88" ref-type="bibr">88</xref>).</p></sec><sec><title>Advanced stage and metastatic disease</title><p>Significant innovation has led to new therapies for advanced NSCLC in recent decades, and it is thought that over half of patients with advanced NSCLC may have an actionable mutation towards which systemic therapy can be directed. Epidermal growth factor receptor (EGFR)-targeted therapies were introduced in 2003; immune checkpoint inhibitors (ICI) have been Food and Drug Administration (FDA)-approved for treatment of lung cancer since 2015 (<xref rid="r89" ref-type="bibr">89</xref>). Currently, the National Comprehensive Cancer Network recommends testing for the several biomarkers in advanced or metastatic disease, including <italic toggle="yes">EGFR</italic>, <italic toggle="yes">KRAS</italic>, <italic toggle="yes">HER2</italic>, <italic toggle="yes">ALK</italic>, <italic toggle="yes">ROS1</italic>, and PD-L1 expression (<xref rid="r90" ref-type="bibr">90</xref>). Responses to modern systemic therapies vary greatly between males and females, emphasizing fundamental differences in their respective diseases (<xref rid="r68" ref-type="bibr">68</xref>). In comparison, older studies demonstrate that traditional chemotherapy offers marginal benefit (on the order of months) to females over males in certain subgroups (<xref rid="r91" ref-type="bibr">91</xref>). In the age of precision medicine, it will become increasingly important to consider biological sex in the lung cancer treatment strategy (<xref rid="r92" ref-type="bibr">92</xref>,<xref rid="r93" ref-type="bibr">93</xref>).</p></sec><sec><title>Targeted therapy</title><p>Multiple meta-analyses have been performed to evaluate the efficacy of EGFR inhibitors. There is disagreement on whether EGFR-tyrosine kinase inhibitor (EGFR TKI) confer tangible benefit to females with NSCLC. A meta-analysis of six phase-three trials comparing EGFR-TKI to chemotherapy in patients with identified EGFR mutations, females were shown to have improved progression-free survival (HR, 0.34; 95% CI: 0.28&#8211;0.40) compared to males (HR, 0.44; 95% CI: 0.34&#8211;0.56), though high heterogeneity was noted in the female group (<xref rid="r92" ref-type="bibr">92</xref>). Conversely, in a meta-analysis of 22 studies, Xiao <italic toggle="yes">et al.</italic> found that only in the subgroup analysis comparing EGFR-TKI to placebo did females demonstrate improved overall survival compared to males. There was no improved survival noted when EGFR-TKI was compared to chemotherapy (HR, 1.01; 95% CI: 0.89&#8211;1.14; P=0.89) or when only patients with known EGFR mutation were considered (HR, 1.02; 95% CI: 0.78&#8211;1.34; P=0.86) (<xref rid="r68" ref-type="bibr">68</xref>). As noted in the recent review by Huang <italic toggle="yes">et al.</italic>, it appears that first- and second-generation EGFR-TKI offer longer progression-free survival to females, which may indicate &#8220;immediate response to treatment&#8221; and inherently does not consider patient characteristics which impact overall survival (<xref rid="r93" ref-type="bibr">93</xref>).</p><p><italic toggle="yes">ALK</italic> and <italic toggle="yes">ROS1</italic> rearrangements also offer opportunity for targeted therapy. They represent a relatively small percentage of NSCLC patients, 3% to 8% of the former and 1% to 2% of the latter, though studies have found these mutations more prevalent in women (<xref rid="r94" ref-type="bibr">94</xref>,<xref rid="r95" ref-type="bibr">95</xref>). There is no current evidence to identify sex differences in treatment and survival outcomes with ALK and ROS1 inhibitors (<xref rid="r59" ref-type="bibr">59</xref>,<xref rid="r93" ref-type="bibr">93</xref>).</p></sec><sec><title>Immunotherapy</title><p>For patients without a known driver mutation, immunotherapy is considered. These drugs block negative regulators PD-1, PD-L1, and CTLA-4 of the immune system. Six meta-analyses generated in our literature search have investigated sex differences in ICI efficacy. Essentially, findings have been inconsistent across these analyses, which are summarized in <xref rid="t3" ref-type="table"><italic toggle="yes">Table 3</italic></xref>. Given results of early meta-analyses, Conforti <italic toggle="yes">et al.</italic> hypothesized that females could benefit from treatment other than immunotherapy alone. A subsequent meta-analysis demonstrated that women experienced a large survival benefit with anti-PD-1 or anti-PD-L1 therapy in combination with chemotherapy with a pooled HR of 0.44 compared to the male HR of 0.76 (<xref rid="r96" ref-type="bibr">96</xref>). It was thought the addition of chemotherapy enhanced the antigenicity of tumor cells, thus prompting the female immune system to respond more vigorously (<xref rid="r96" ref-type="bibr">96</xref>). A follow-up study found that despite having high PD-L1 expression, defined as tumor proportion score &#8805;50%, females did not derive statistically significant benefit from ICI monotherapy (<xref rid="r61" ref-type="bibr">61</xref>). In their review on gender differences in immunotherapy outcomes, Vaval&#224; <italic toggle="yes">et al.</italic> appropriately highlights that heterogeneity within randomized-controlled trials, lack of subgroup data, and relatively short follow-up allow only conjecture, but not durable conclusions, to be drawn from these analyses (<xref rid="r46" ref-type="bibr">46</xref>). As plainly demonstrated in <xref rid="t3" ref-type="table"><italic toggle="yes">Table 3</italic></xref>, the heterogeneity of the intervention and control arms offers an avenue for bias introduction in these investigations.</p><table-wrap position="float" id="t3" orientation="portrait"><label>Table 3</label><caption><title>Recent meta-analyses examining sex differences in efficacy of ICIs in treating NSCLC</title></caption><table frame="hsides" rules="groups"><col width="7.07%" span="1"/><col width="10.19%" span="1"/><col width="5.83%" span="1"/><col width="32%" span="1"/><col width="21.18%" span="1"/><col width="23.73%" span="1"/><thead><tr><th valign="middle" align="left" scope="col" rowspan="1" colspan="1">Meta-analysis, year published</th><th valign="middle" align="center" scope="col" rowspan="1" colspan="1">Number of patients included [number of studies included]</th><th valign="middle" align="center" scope="col" rowspan="1" colspan="1">Number of female participants (%)</th><th valign="middle" align="center" scope="col" rowspan="1" colspan="1">Intervention <italic toggle="yes">vs.</italic> control arms, and clarifying comments</th><th valign="middle" align="center" scope="col" rowspan="1" colspan="1">Pooled HR (95% CI)</th><th valign="middle" align="center" scope="col" rowspan="1" colspan="1">Conclusions</th></tr></thead><tbody><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Conforti, 2018 (<xref rid="r60" ref-type="bibr">60</xref>)</td><td valign="top" align="center" rowspan="1" colspan="1">3,482 [6]</td><td valign="top" align="center" rowspan="1" colspan="1">1,167 (33.5)</td><td valign="top" align="center" rowspan="1" colspan="1">PD-1 inhibitor or CTLA-4 inhibitor plus chemotherapy <italic toggle="yes">vs.</italic> chemotherapy or chemotherapy plus placebo</td><td valign="top" align="center" rowspan="1" colspan="1">Overall survival compared to controls: male: 0.72 (0.61&#8211;0.86); female: 0.89 (0.71&#8211;1.11)</td><td valign="top" align="center" rowspan="1" colspan="1">Advanced or metastatic cancers were studied, of which NSCLC was a subgroup. In the overall study of 20 trials and 11,351 patients, pooled male survival was 0.72 (0.65&#8211;0.79) and female survival 0.86 (0.79&#8211;0.93) with a significant difference in efficacy between sexes (P=0.0019), demonstrating sex-specific benefit in overall survival with ICI therapy</td></tr><tr><td rowspan="4" valign="top" align="left" scope="row" colspan="1">Conforti, 2019 (<xref rid="r96" ref-type="bibr">96</xref>)</td><td valign="top" align="center" rowspan="1" colspan="1">2,970<sup>&#8224;</sup> [5]</td><td valign="top" align="center" rowspan="1" colspan="1">991 (33.4)</td><td rowspan="2" valign="top" align="center" colspan="1">PD-1/PD-L1 inhibitor plus chemotherapy <italic toggle="yes">vs.</italic> chemotherapy. When excluding the trial with SCLC patients, a statistically significant overall survival benefit for females compared to males remained</td><td valign="top" align="center" rowspan="1" colspan="1">Overall survival: male: 0.76 (0.66&#8211;0.87); female: 0.48 (0.35&#8211;0.67)</td><td rowspan="4" valign="top" align="center" colspan="1">Females with advanced NSCLC derive greater benefit from combination chemoimmunotherapy than males, though both demonstrate improved survival with combination therapy over chemotherapy alone. However, only males demonstrate benefit from anti-PD-1 alone over chemotherapy</td></tr><tr><td valign="top" colspan="1" align="center" scope="row" rowspan="1">4,923<sup>&#8225;</sup> [8]</td><td valign="top" align="center" rowspan="1" colspan="1">1,578 (32.1)</td><td valign="top" colspan="1" align="center" rowspan="1">Progression-free survival: male: 0.64 (0.58&#8211;0.71); female: 0.56 (0.49&#8211;0.65)</td></tr><tr><td rowspan="2" valign="top" colspan="1" align="center" scope="row">3,974 [6]</td><td rowspan="2" valign="top" align="center" colspan="1">1,335 (33.6)</td><td rowspan="2" valign="top" align="center" colspan="1">PD-1/PD-L1 inhibitor plus chemotherapy <italic toggle="yes">vs.</italic> chemotherapy (first-line treatment). Three studies tested PD-1 alone; 3 studies tested PD-1/PD-L1 with chemotherapy</td><td valign="top" align="center" rowspan="1" colspan="1">Overall survival for anti-PD-1: male: 0.78 (0.60&#8211;1.01); female: 0.97 (0.79&#8211;1.19)</td></tr><tr><td valign="top" colspan="1" align="center" scope="col" rowspan="1">Overall survival for anti-PD-1/PD-L1 with chemotherapy: male: 0.76 (0.64&#8211;0.91); female: 0.44 (0.25&#8211;0.76)</td></tr><tr><td rowspan="2" valign="top" align="left" scope="row" colspan="1">Wang, 2019 (<xref rid="r97" ref-type="bibr">97</xref>)</td><td valign="top" align="center" rowspan="1" colspan="1">8,023 [12]</td><td valign="top" align="center" rowspan="1" colspan="1">2,601 (32.4)</td><td valign="top" align="center" rowspan="1" colspan="1">PD-1/PD-L1 inhibitor alone or PD-1 or CTLA-4 inhibitor plus chemotherapy or PD-L1 plus chemoradiotherapy <italic toggle="yes">vs.</italic> chemotherapy or chemoradiotherapy</td><td valign="top" align="center" rowspan="1" colspan="1">Overall survival: male: 0.76 (0.71&#8211;0.82); female: 0.73 (0.58&#8211;0.91)</td><td rowspan="2" valign="top" align="center" colspan="1">Males experience more reliable benefit from ICIs than females. However, CTLA-4 inhibitors did not demonstrate survival benefit for either sex</td></tr><tr><td valign="top" colspan="1" align="center" scope="row" rowspan="1">5,622 [10]</td><td valign="top" align="center" rowspan="1" colspan="1">1,934 (34.4)</td><td valign="top" align="center" rowspan="1" colspan="1">PD-1 alone, PD-1 plus CTLA-4 inhibitor, PD-1 plus chemotherapy, PD-L1 inhibitor plus chemotherapy or chemoradiotherapy <italic toggle="yes">vs.</italic> chemotherapy or chemoradiotherapy</td><td valign="top" align="center" rowspan="1" colspan="1">Progression-free survival: male: 0.67 (0.58&#8211;0.77); female: 0.73 (0.56&#8211;0.95)</td></tr><tr><td rowspan="2" valign="top" align="left" scope="row" colspan="1">Xue, 2021 (<xref rid="r98" ref-type="bibr">98</xref>)</td><td valign="top" align="center" rowspan="1" colspan="1">12,037 [19]</td><td valign="top" align="center" rowspan="1" colspan="1">3,751 (31.2)</td><td valign="top" align="center" rowspan="1" colspan="1">PD-1, PD-L1, CTLA-4 inhibitor, or CTLA-4 plus PD-1 inhibitor together or PD-1, PD-L1, CTLA-4 inhibitor plus chemotherapy <italic toggle="yes">vs.</italic> chemotherapy or chemotherapy plus placebo</td><td valign="top" align="center" rowspan="1" colspan="1">Overall survival: male: 0.73 (0.67&#8211;0.79); female: 0.73 (0.61&#8211;0.85)</td><td rowspan="2" valign="top" align="center" colspan="1">Both males and females benefit from treatment with ICI over chemotherapy. There is no significant difference in overall survival (P=0.97) and progression-free survival (P=0.43) between the sexes</td></tr><tr><td valign="top" colspan="1" align="center" scope="row" rowspan="1">6,940 [14]</td><td valign="top" align="center" rowspan="1" colspan="1">2,088 (30.1)</td><td valign="top" align="center" rowspan="1" colspan="1">PD-1, PD-L1, or CTLA-4 plus PD-1 inhibitor together or PD-1 or PD-L1 inhibitor plus chemotherapy <italic toggle="yes">vs.</italic> chemotherapy or chemotherapy plus placebo</td><td valign="top" align="center" rowspan="1" colspan="1">Progression-free survival: male: 0.62 (0.55&#8211;0.70); female: 0.68 (0.55&#8211;0.81)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Liang, 2022 (<xref rid="r99" ref-type="bibr">99</xref>)</td><td valign="top" align="center" rowspan="1" colspan="1">10,155 [16]</td><td valign="top" align="center" rowspan="1" colspan="1">3,370 (33.2)</td><td valign="top" align="center" rowspan="1" colspan="1">PD-1/PD-L1 or CTLA-4 inhibitor alone, in combination, or with chemotherapy <italic toggle="yes">vs.</italic> chemotherapy or placebo. Six studies tested ICI plus chemotherapy <italic toggle="yes">vs.</italic> chemotherapy, 9 studies compared ICI <italic toggle="yes">vs.</italic> chemotherapy, and 1 study reviewed ICI <italic toggle="yes">vs.</italic> placebo</td><td valign="top" align="center" rowspan="1" colspan="1">Overall survival: male: 0.76 (0.71&#8211;0.81); female: 0.74 (0.63&#8211;0.87)</td><td valign="top" align="center" rowspan="1" colspan="1">In general, females benefitted more from combination chemoimmunotherapy, while males benefitted more from ICIs alone. However, in squamous cell carcinoma, only males demonstrated a statistically significant benefit from ICI therapy, either with or without chemotherapy</td></tr><tr><td rowspan="2" valign="top" align="left" scope="row" colspan="1">Madala, 2022 (<xref rid="r100" ref-type="bibr">100</xref>)</td><td valign="top" align="center" rowspan="1" colspan="1">9,270 [12]</td><td valign="top" align="center" rowspan="1" colspan="1">3,144 (33.9)</td><td rowspan="2" valign="top" align="center" colspan="1">PD-1/PD-L1 inhibitor alone or combined with chemotherapy <italic toggle="yes">vs.</italic> chemotherapy, placebo, or their combination</td><td valign="top" align="center" rowspan="1" colspan="1">Overall survival: male: 0.74 (0.66&#8211;0.83); female: 0.72 (0.63&#8211;0.82)</td><td rowspan="2" valign="top" align="center" colspan="1">No statistical difference was found in overall survival (P=0.709) and progression-free survival (P=0.372) between the sexes</td></tr><tr><td valign="top" colspan="1" align="center" scope="row" rowspan="1">6,193 [11]</td><td valign="top" align="center" rowspan="1" colspan="1">2,059 (33.2)</td><td valign="top" colspan="1" align="center" rowspan="1">Progression-free survival: male: 0.63 (0.53&#8211;0.75); female: 0.72 (0.58&#8211;0.88)</td></tr><tr><td rowspan="2" valign="top" align="left" scope="row" colspan="1">Takada, 2022 (<xref rid="r101" ref-type="bibr">101</xref>)</td><td valign="top" align="center" rowspan="1" colspan="1">5,280 [8]</td><td valign="top" align="center" rowspan="1" colspan="1">1,554 (29.4)</td><td valign="top" align="center" rowspan="1" colspan="1">PD-1/PD-L1 or CTLA-4 inhibitor, or PD-1 plus CTLA-4 inhibitor in combination, or PD-L1 + VEGF inhibitor in combination plus chemotherapy <italic toggle="yes">vs.</italic> chemotherapy, placebo plus chemotherapy, or VEGF inhibitor plus chemotherapy</td><td valign="top" align="center" rowspan="1" colspan="1">Overall survival: male: 0.80 (0.72&#8211;0.87); female: 0.69 (0.54&#8211;0.89)</td><td rowspan="2" valign="top" align="center" colspan="1">During first-line treatment, patients with advanced NSCLC demonstrated both improved overall survival and progression-free survival when treated with combined chemoimmunotherapy rather than chemotherapy alone, though this favors females to a greater degree</td></tr><tr><td valign="top" colspan="1" align="center" scope="row" rowspan="1">3,701 [6]</td><td valign="top" align="center" rowspan="1" colspan="1">1,184 (32.0)</td><td valign="top" align="center" rowspan="1" colspan="1">PD-1/PD-L1 inhibitor or PD-1 plus CTLA-4 inhibitor in combination, or PD-L1 + VEGF inhibitor in combination plus chemotherapy <italic toggle="yes">vs.</italic> chemotherapy, placebo plus chemotherapy, or VEGF inhibitor, placebo, and chemotherapy</td><td valign="top" align="center" rowspan="1" colspan="1">Progression-free survival: male: 0.60 (0.55&#8211;0.66); female: 0.56 (0.44&#8211;0.70)</td></tr></tbody></table><table-wrap-foot><p><sup>&#8224;</sup>, 13.6% of patients with SCLC; <sup>&#8225;</sup>, 8.2% of patients with SCLC. ICI, immune checkpoint inhibitor; NSCLC, non-small cell lung cancer; HR, hazard ratio; CI, confidence interval; SCLC, small cell lung cancer; VEGF, vascular endothelial growth factor.</p></table-wrap-foot></table-wrap><p>Another important factor for consideration is the risk that comes ICI treatment. Females treated with anti-PD-1 therapy were more likely to experience immune-related adverse events (48% <italic toggle="yes">vs.</italic> 31%, P&lt;0.008), notably pneumonitis and endocrinopathies, in a retrospective review of NSCLC patients. They were also more were likely than males to discontinue the offending agent secondary to side effects (17% <italic toggle="yes">vs.</italic> 7%, P&lt;0.04). Multivariable analysis examining patient and tumor factors found that only sex was associated with an increased risk of these adverse events. Interestingly, females who experienced immune-related adverse events more frequently demonstrated radiographic response when evaluated several weeks following initiation of ICI therapy (78% <italic toggle="yes">vs.</italic> 23%, P&lt;0.0001) and had longer progression-free survival (10 <italic toggle="yes">vs.</italic> 3.3 months, P&lt;0.0006) compared to females with no adverse events. This distinction was not statistically significant in males. Ultimately though, there was no association between immune-related adverse events and overall survival in the NSCLC cohort (<xref rid="r102" ref-type="bibr">102</xref>).</p><p>The limitations of this narrative review must be acknowledged. A single database was used to collect relevant literature, and articles were selected based on relevancy as determined by the authors&#8217; expertise. Our review is not an exhaustive examination of all data published on this topic.</p></sec></sec><sec sec-type="conclusions"><title>Conclusions</title><p>Increasing lung cancer incidence in non-smokers and young females begs demands greater understanding of sex-based drivers of the disease. Environmental exposure studies, especially those which examine risk factors present in the home, are lacking, the effect of sex hormones on carcinogenesis in the lung is not well understood, and females continue to be underrepresented in clinical trials for lung cancer treatment. Randomized controlled trials with uniform control arms are necessary to truly optimize treatment regimens with new systemic therapies. Practically-speaking, clinicians must recognize that current screening guidelines do not reflect the changing demographics seen in new lung cancer diagnoses. Further investigation into the sex-specific differences in lung cancer will not only increase the proportion of patients diagnosed in its early stages, but also generate sex-based treatment modalities.</p></sec><sec sec-type="supplementary-material"><title>Supplementary</title><supplementary-material position="float" content-type="local-data" orientation="portrait"><p>The article&#8217;s supplementary files as</p></supplementary-material><supplementary-material position="anchor" id="su1" content-type="local-data" orientation="portrait"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="tlcr-13-01-163-rc.pdf" id="d66e1413" position="anchor" orientation="portrait"><object-id pub-id-type="doi">10.21037/tlcr-23-744</object-id></media><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="tlcr-13-01-163-prf.pdf" id="d66e1416" position="anchor" orientation="portrait"><object-id pub-id-type="doi">10.21037/tlcr-23-744</object-id></media><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="tlcr-13-01-163-coif.pdf" id="d66e1419" position="anchor" orientation="portrait"><object-id pub-id-type="doi">10.21037/tlcr-23-744</object-id></media></supplementary-material></sec></body><back><ack><title>Acknowledgments</title><p><italic toggle="yes">Funding:</italic> This work was supported by <funding-source rid="sp1">the Department of Thoracic Surgery at Roswell Park Comprehensive Cancer Center and the University of Tennessee Graduate School of Medicine</funding-source>.</p></ack><fn-group><fn id="fn1"><p><italic toggle="yes">Reporting Checklist:</italic> The authors have completed the Narrative Review reporting checklist. Available at <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://tlcr.amegroups.com/article/view/10.21037/tlcr-23-744/rc" ext-link-type="uri">https://tlcr.amegroups.com/article/view/10.21037/tlcr-23-744/rc</ext-link></p></fn><fn id="fn2"><p><italic toggle="yes">Peer Review File:</italic> Available at <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://tlcr.amegroups.com/article/view/10.21037/tlcr-23-744/prf" ext-link-type="uri">https://tlcr.amegroups.com/article/view/10.21037/tlcr-23-744/prf</ext-link></p></fn><fn fn-type="COI-statement"><p><italic toggle="yes">Conflicts of Interest:</italic> Both authors have completed the ICMJE uniform disclosure form (available at <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://tlcr.amegroups.com/article/view/10.21037/tlcr-23-744/coif" ext-link-type="uri">https://tlcr.amegroups.com/article/view/10.21037/tlcr-23-744/coif</ext-link>). S.Y. is a scientific advisory board member of Karkinos Healthcare, receives grant funding from Lumeda Inc., and serves as an unpaid editorial board member of <italic toggle="yes">Translational Lung Cancer Research</italic> from October 2023 to September 2025. The other author has no conflicts of interest to declare.</p></fn></fn-group><notes><p content-type="note added in proof"><italic toggle="yes">Ethical Statement:</italic> The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.</p></notes><ref-list><title>References</title><ref id="r1"><label>1</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ridge</surname><given-names>CA</given-names></name><name name-style="western"><surname>McErlean</surname><given-names>AM</given-names></name><name name-style="western"><surname>Ginsberg</surname><given-names>MS</given-names></name></person-group>. <article-title>Epidemiology of lung cancer.</article-title><source>Semin Intervent Radiol</source><year>2013</year>;<volume>30</volume>:<fpage>93</fpage>-<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1055/s-0033-1342949</pub-id><pub-id pub-id-type="pmid">24436524</pub-id><pub-id pub-id-type="pmcid">PMC3709917</pub-id></mixed-citation></ref><ref id="r2"><label>2</label><mixed-citation publication-type="webpage">World Health Organization. Lung cancer. 2023. Accessed July 25, 2023. Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.who.int/news-room/fact-sheets/detail/lung-cancer" ext-link-type="uri">https://www.who.int/news-room/fact-sheets/detail/lung-cancer</ext-link></mixed-citation></ref><ref id="r3"><label>3</label><mixed-citation publication-type="webpage">World Health Organization. Cancer. 2022. Accessed July 25 2023. Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.who.int/news-room/fact-sheets/detail/cancer" ext-link-type="uri">https://www.who.int/news-room/fact-sheets/detail/cancer</ext-link></mixed-citation></ref><ref id="r4"><label>4</label><mixed-citation publication-type="webpage">U.S. Cancer Statistics Working Group. U.S. Cancer Statistics Data Visualizations Tool, based on 2022 submission data (1999-2020): U.S. Department of Health and Human Services, Centers for Disease Control and Prevention and National Cancer Institute. 2023. Accessed January 5, 2024. Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.cdc.gov/cancer/dataviz" ext-link-type="uri">https://www.cdc.gov/cancer/dataviz</ext-link></mixed-citation></ref><ref id="r5"><label>5</label><mixed-citation publication-type="webpage">Cancer Facts &amp; Figures 2023. Atlanta: American Cancer Society, Inc.; 2022. Accessed January 9, 2024. Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2023/2023-cancer-facts-and-figures.pdf" ext-link-type="uri">https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2023/2023-cancer-facts-and-figures.pdf</ext-link></mixed-citation></ref><ref id="r6"><label>6</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Meza</surname><given-names>R</given-names></name><name name-style="western"><surname>Meernik</surname><given-names>C</given-names></name><name name-style="western"><surname>Jeon</surname><given-names>J</given-names></name><etal/></person-group><article-title>Lung cancer incidence trends by gender, race and histology in the United States, 1973-2010.</article-title><source>PLoS One</source><year>2015</year>;<volume>10</volume>:<elocation-id>e0121323</elocation-id> .<pub-id pub-id-type="doi">10.1371/journal.pone.0121323</pub-id><pub-id pub-id-type="pmid">25822850</pub-id><pub-id pub-id-type="pmcid">PMC4379166</pub-id></mixed-citation></ref><ref id="r7"><label>7</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dela Cruz</surname><given-names>CS</given-names></name><name name-style="western"><surname>Tanoue</surname><given-names>LT</given-names></name><name name-style="western"><surname>Matthay</surname><given-names>RA</given-names></name></person-group>. <article-title>Lung cancer: epidemiology, etiology, and prevention.</article-title><source>Clin Chest Med</source><year>2011</year>;<volume>32</volume>:<fpage>605</fpage>-<lpage>44</lpage>. <pub-id pub-id-type="doi">10.1016/j.ccm.2011.09.001</pub-id><pub-id pub-id-type="pmid">22054876</pub-id><pub-id pub-id-type="pmcid">PMC3864624</pub-id></mixed-citation></ref><ref id="r8"><label>8</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ragavan</surname><given-names>MV</given-names></name><name name-style="western"><surname>Patel</surname><given-names>MI</given-names></name></person-group>. <article-title>Understanding sex disparities in lung cancer incidence: are women more at risk?</article-title><source>Lung Cancer Manag</source><year>2020</year>;<volume>9</volume>:<fpage>LMT34</fpage> .<pub-id pub-id-type="doi">10.2217/lmt-2020-0013</pub-id><pub-id pub-id-type="pmid">32774466</pub-id><pub-id pub-id-type="pmcid">PMC7399577</pub-id></mixed-citation></ref><ref id="r9"><label>9</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hsu</surname><given-names>LH</given-names></name><name name-style="western"><surname>Chu</surname><given-names>NM</given-names></name><name name-style="western"><surname>Kao</surname><given-names>SH</given-names></name></person-group>. <article-title>Estrogen, Estrogen Receptor and Lung Cancer.</article-title><source>Int J Mol Sci</source><year>2017</year>;<volume>18</volume>:<fpage>1713</fpage> .<pub-id pub-id-type="doi">10.3390/ijms18081713</pub-id><pub-id pub-id-type="pmid">28783064</pub-id><pub-id pub-id-type="pmcid">PMC5578103</pub-id></mixed-citation></ref><ref id="r10"><label>10</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bade</surname><given-names>BC</given-names></name><name name-style="western"><surname>Dela Cruz</surname><given-names>CS</given-names></name></person-group>. <article-title>Lung Cancer 2020: Epidemiology, Etiology, and Prevention.</article-title><source>Clin Chest Med</source><year>2020</year>;<volume>41</volume>:<fpage>1</fpage>-<lpage>24</lpage>. <pub-id pub-id-type="doi">10.1016/j.ccm.2019.10.001</pub-id><pub-id pub-id-type="pmid">32008623</pub-id></mixed-citation></ref><ref id="r11"><label>11</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jeon</surname><given-names>J</given-names></name><name name-style="western"><surname>Holford</surname><given-names>TR</given-names></name><name name-style="western"><surname>Levy</surname><given-names>DT</given-names></name><etal/></person-group><article-title>Smoking and Lung Cancer Mortality in the United States From 2015 to 2065: A Comparative Modeling Approach.</article-title><source>Ann Intern Med</source><year>2018</year>;<volume>169</volume>:<fpage>684</fpage>-<lpage>93</lpage>. <pub-id pub-id-type="doi">10.7326/M18-1250</pub-id><pub-id pub-id-type="pmid">30304504</pub-id><pub-id pub-id-type="pmcid">PMC6242740</pub-id></mixed-citation></ref><ref id="r12"><label>12</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Song</surname><given-names>MA</given-names></name><name name-style="western"><surname>Benowitz</surname><given-names>NL</given-names></name><name name-style="western"><surname>Berman</surname><given-names>M</given-names></name><etal/></person-group><article-title>Cigarette Filter Ventilation and its Relationship to Increasing Rates of Lung Adenocarcinoma.</article-title><source>J Natl Cancer Inst</source><year>2017</year>;<volume>109</volume>:<elocation-id>djx075</elocation-id> .<pub-id pub-id-type="doi">10.1093/jnci/djx075</pub-id><pub-id pub-id-type="pmid">28525914</pub-id><pub-id pub-id-type="pmcid">PMC6059254</pub-id></mixed-citation></ref><ref id="r13"><label>13</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Freudenstein</surname><given-names>D</given-names></name><name name-style="western"><surname>Litchfield</surname><given-names>C</given-names></name><name name-style="western"><surname>Caramia</surname><given-names>F</given-names></name><etal/></person-group><article-title>TP53 Status, Patient Sex, and the Immune Response as Determinants of Lung Cancer Patient Survival.</article-title><source>Cancers (Basel)</source><year>2020</year>;<volume>12</volume>:<fpage>1535</fpage> .<pub-id pub-id-type="doi">10.3390/cancers12061535</pub-id><pub-id pub-id-type="pmid">32545367</pub-id><pub-id pub-id-type="pmcid">PMC7352604</pub-id></mixed-citation></ref><ref id="r14"><label>14</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mederos</surname><given-names>N</given-names></name><name name-style="western"><surname>Friedlaender</surname><given-names>A</given-names></name><name name-style="western"><surname>Peters</surname><given-names>S</given-names></name><etal/></person-group><article-title>Gender-specific aspects of epidemiology, molecular genetics and outcome: lung cancer.</article-title><source>ESMO Open</source><year>2020</year>;<volume>5</volume>:<elocation-id>e000796</elocation-id> .<pub-id pub-id-type="doi">10.1136/esmoopen-2020-000796</pub-id><pub-id pub-id-type="pmid">33148544</pub-id><pub-id pub-id-type="pmcid">PMC7643520</pub-id></mixed-citation></ref><ref id="r15"><label>15</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bugge</surname><given-names>A</given-names></name><name name-style="western"><surname>Kongerud</surname><given-names>J</given-names></name><name name-style="western"><surname>Brunborg</surname><given-names>C</given-names></name><etal/></person-group><article-title>Gender-specific survival after surgical resection for early stage non-small cell lung cancer.</article-title><source>Acta Oncol</source><year>2017</year>;<volume>56</volume>:<fpage>448</fpage>-<lpage>54</lpage>. <pub-id pub-id-type="doi">10.1080/0284186X.2016.1253862</pub-id><pub-id pub-id-type="pmid">27846762</pub-id></mixed-citation></ref><ref id="r16"><label>16</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hansen</surname><given-names>MS</given-names></name><name name-style="western"><surname>Licaj</surname><given-names>I</given-names></name><name name-style="western"><surname>Braaten</surname><given-names>T</given-names></name><etal/></person-group><article-title>Sex Differences in Risk of Smoking-Associated Lung Cancer: Results From a Cohort of 600,000 Norwegians.</article-title><source>Am J Epidemiol</source><year>2018</year>;<volume>187</volume>:<fpage>971</fpage>-<lpage>81</lpage>. <pub-id pub-id-type="doi">10.1093/aje/kwx339</pub-id><pub-id pub-id-type="pmid">29087432</pub-id></mixed-citation></ref><ref id="r17"><label>17</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cheng</surname><given-names>TD</given-names></name><name name-style="western"><surname>Darke</surname><given-names>AK</given-names></name><name name-style="western"><surname>Redman</surname><given-names>MW</given-names></name><etal/></person-group><article-title>Smoking, Sex, and Non-Small Cell Lung Cancer: Steroid Hormone Receptors in Tumor Tissue (S0424).</article-title><source>J Natl Cancer Inst</source><year>2018</year>;<volume>110</volume>:<fpage>734</fpage>-<lpage>42</lpage>. <pub-id pub-id-type="doi">10.1093/jnci/djx260</pub-id><pub-id pub-id-type="pmid">29346580</pub-id><pub-id pub-id-type="pmcid">PMC6037104</pub-id></mixed-citation></ref><ref id="r18"><label>18</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stapelfeld</surname><given-names>C</given-names></name><name name-style="western"><surname>Dammann</surname><given-names>C</given-names></name><name name-style="western"><surname>Maser</surname><given-names>E</given-names></name></person-group>. <article-title>Sex-specificity in lung cancer risk.</article-title><source>Int J Cancer</source><year>2020</year>;<volume>146</volume>:<fpage>2376</fpage>-<lpage>82</lpage>. <pub-id pub-id-type="doi">10.1002/ijc.32716</pub-id><pub-id pub-id-type="pmid">31583690</pub-id></mixed-citation></ref><ref id="r19"><label>19</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fuentes</surname><given-names>N</given-names></name><name name-style="western"><surname>Silva Rodriguez</surname><given-names>M</given-names></name><name name-style="western"><surname>Silveyra</surname><given-names>P.</given-names></name></person-group><article-title>Role of sex hormones in lung cancer.</article-title><source>Exp Biol Med (Maywood)</source><year>2021</year>;<volume>246</volume>:<fpage>2098</fpage>-<lpage>110</lpage>. <pub-id pub-id-type="doi">10.1177/15353702211019697</pub-id><pub-id pub-id-type="pmid">34080912</pub-id><pub-id pub-id-type="pmcid">PMC8524770</pub-id></mixed-citation></ref><ref id="r20"><label>20</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Siegfried</surname><given-names>JM</given-names></name></person-group>. <article-title>Sex and Gender Differences in Lung Cancer and Chronic Obstructive Lung Disease.</article-title><source>Endocrinology</source><year>2022</year>;<volume>163</volume>:<elocation-id>bqab254</elocation-id> .<pub-id pub-id-type="doi">10.1210/endocr/bqab254</pub-id><pub-id pub-id-type="pmid">34927202</pub-id></mixed-citation></ref><ref id="r21"><label>21</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Liu</surname><given-names>H</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>S</given-names></name><etal/></person-group><article-title>Gender susceptibility for cigarette smoking-attributable lung cancer: a systematic review and meta-analysis.</article-title><source>Lung Cancer</source><year>2014</year>;<volume>85</volume>:<fpage>351</fpage>-<lpage>60</lpage>. <pub-id pub-id-type="doi">10.1016/j.lungcan.2014.07.004</pub-id><pub-id pub-id-type="pmid">25064415</pub-id></mixed-citation></ref><ref id="r22"><label>22</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ben-Zaken Cohen</surname><given-names>S</given-names></name><name name-style="western"><surname>Par&#233;</surname><given-names>PD</given-names></name><name name-style="western"><surname>Man</surname><given-names>SF</given-names></name><etal/></person-group><article-title>The growing burden of chronic obstructive pulmonary disease and lung cancer in women: examining sex differences in cigarette smoke metabolism.</article-title><source>Am J Respir Crit Care Med</source><year>2007</year>;<volume>176</volume>:<fpage>113</fpage>-<lpage>20</lpage>. <pub-id pub-id-type="doi">10.1164/rccm.200611-1655PP</pub-id><pub-id pub-id-type="pmid">17413125</pub-id></mixed-citation></ref><ref id="r23"><label>23</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wijesinghe</surname><given-names>AI</given-names></name><name name-style="western"><surname>Kobayashi</surname><given-names>N</given-names></name><name name-style="western"><surname>Kitazawa</surname><given-names>S</given-names></name><etal/></person-group><article-title>Sex-specific emphysematous changes evaluated by a three-dimensional computed tomography volumetric analysis among patients with smoking histories who underwent resection for lung cancer.</article-title><source>Surg Today</source><year>2024</year>;<volume>54</volume>:<fpage>113</fpage>-<lpage>21</lpage>. <pub-id pub-id-type="doi">10.1007/s00595-023-02707-8</pub-id><pub-id pub-id-type="pmid">37271799</pub-id></mixed-citation></ref><ref id="r24"><label>24</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cl&#233;ment-Duch&#234;ne</surname><given-names>C</given-names></name><name name-style="western"><surname>Vignaud</surname><given-names>JM</given-names></name><name name-style="western"><surname>Stoufflet</surname><given-names>A</given-names></name><etal/></person-group><article-title>Characteristics of never smoker lung cancer including environmental and occupational risk factors.</article-title><source>Lung Cancer</source><year>2010</year>;<volume>67</volume>:<fpage>144</fpage>-<lpage>50</lpage>. <pub-id pub-id-type="doi">10.1016/j.lungcan.2009.04.005</pub-id><pub-id pub-id-type="pmid">19464070</pub-id></mixed-citation></ref><ref id="r25"><label>25</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Baiu</surname><given-names>I</given-names></name><name name-style="western"><surname>Titan</surname><given-names>AL</given-names></name><name name-style="western"><surname>Martin</surname><given-names>LW</given-names></name><etal/></person-group><article-title>The role of gender in non-small cell lung cancer: a narrative review.</article-title><source>J Thorac Dis</source><year>2021</year>;<volume>13</volume>:<fpage>3816</fpage>-<lpage>26</lpage>. <pub-id pub-id-type="doi">10.21037/jtd-20-3128</pub-id><pub-id pub-id-type="pmid">34277072</pub-id><pub-id pub-id-type="pmcid">PMC8264700</pub-id></mixed-citation></ref><ref id="r26"><label>26</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Huang</surname><given-names>J</given-names></name><name name-style="western"><surname>Yue</surname><given-names>N</given-names></name><name name-style="western"><surname>Shi</surname><given-names>N</given-names></name><etal/></person-group><article-title>Influencing factors of lung cancer in nonsmoking women: systematic review and meta-analysis.</article-title><source>J Public Health (Oxf)</source><year>2022</year>;<volume>44</volume>:<fpage>259</fpage>-<lpage>68</lpage>. <pub-id pub-id-type="doi">10.1093/pubmed/fdaa254</pub-id><pub-id pub-id-type="pmid">33429425</pub-id></mixed-citation></ref><ref id="r27"><label>27</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lin</surname><given-names>PC</given-names></name><name name-style="western"><surname>Peng</surname><given-names>CY</given-names></name><name name-style="western"><surname>Pan</surname><given-names>CH</given-names></name><etal/></person-group><article-title>Gender differences and lung cancer risk in occupational chefs: analyzing more than 350,000 chefs in Taiwan, 1984-2011.</article-title><source>Int Arch Occup Environ Health</source><year>2019</year>;<volume>92</volume>:<fpage>101</fpage>-<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1007/s00420-018-1358-8</pub-id><pub-id pub-id-type="pmid">30225650</pub-id><pub-id pub-id-type="pmcid">PMC6323082</pub-id></mixed-citation></ref><ref id="r28"><label>28</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Betansedi</surname><given-names>CO</given-names></name><name name-style="western"><surname>Vaca Vasquez</surname><given-names>P</given-names></name><name name-style="western"><surname>Counil</surname><given-names>E</given-names></name></person-group>. <article-title>A comprehensive approach of the gender bias in occupational cancer epidemiology: A systematic review of lung cancer studies (2003-2014).</article-title><source>Am J Ind Med</source><year>2018</year>;<volume>61</volume>:<fpage>372</fpage>-<lpage>82</lpage>. <pub-id pub-id-type="doi">10.1002/ajim.22823</pub-id><pub-id pub-id-type="pmid">29508431</pub-id></mixed-citation></ref><ref id="r29"><label>29</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Boice</surname><given-names>JD</given-names><suffix>Jr</suffix></name><name name-style="western"><surname>Ellis</surname><given-names>ED</given-names></name><name name-style="western"><surname>Golden</surname><given-names>AP</given-names></name><etal/></person-group><article-title>Sex-specific lung cancer risk among radiation workers in the million-person study and patients TB-Fluoroscopy.</article-title><source>Int J Radiat Biol</source><year>2022</year>;<volume>98</volume>:<fpage>769</fpage>-<lpage>80</lpage>. <pub-id pub-id-type="doi">10.1080/09553002.2018.1547441</pub-id><pub-id pub-id-type="pmid">30614747</pub-id></mixed-citation></ref><ref id="r30"><label>30</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ragavan</surname><given-names>M</given-names></name><name name-style="western"><surname>Patel</surname><given-names>MI</given-names></name></person-group>. <article-title>The evolving landscape of sex-based differences in lung cancer: a distinct disease in women.</article-title><source>Eur Respir Rev</source><year>2022</year>;<volume>31</volume>:<elocation-id>210100</elocation-id> .<pub-id pub-id-type="doi">10.1183/16000617.0100-2021</pub-id><pub-id pub-id-type="pmid">35022255</pub-id><pub-id pub-id-type="pmcid">PMC9488944</pub-id></mixed-citation></ref><ref id="r31"><label>31</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pinheiro</surname><given-names>PS</given-names></name><name name-style="western"><surname>Callahan</surname><given-names>KE</given-names></name><name name-style="western"><surname>Medina</surname><given-names>HN</given-names></name><etal/></person-group><article-title>Lung cancer in never smokers: Distinct population-based patterns by age, sex, and race/ethnicity.</article-title><source>Lung Cancer</source><year>2022</year>;<volume>174</volume>:<fpage>50</fpage>-<lpage>6</lpage>. <pub-id pub-id-type="doi">10.1016/j.lungcan.2022.10.009</pub-id><pub-id pub-id-type="pmid">36334356</pub-id></mixed-citation></ref><ref id="r32"><label>32</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Weiss</surname><given-names>JM</given-names></name><name name-style="western"><surname>Lacey</surname><given-names>JV</given-names><suffix>Jr</suffix></name><name name-style="western"><surname>Shu</surname><given-names>XO</given-names></name><etal/></person-group><article-title>Menstrual and reproductive factors in association with lung cancer in female lifetime nonsmokers.</article-title><source>Am J Epidemiol</source><year>2008</year>;<volume>168</volume>:<fpage>1319</fpage>-<lpage>25</lpage>. <pub-id pub-id-type="doi">10.1093/aje/kwn257</pub-id><pub-id pub-id-type="pmid">18849300</pub-id><pub-id pub-id-type="pmcid">PMC4447775</pub-id></mixed-citation></ref><ref id="r33"><label>33</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schwartz</surname><given-names>AG</given-names></name><name name-style="western"><surname>Ray</surname><given-names>RM</given-names></name><name name-style="western"><surname>Cote</surname><given-names>ML</given-names></name><etal/></person-group><article-title>Hormone Use, Reproductive History, and Risk of Lung Cancer: The Women's Health Initiative Studies.</article-title><source>J Thorac Oncol</source><year>2015</year>;<volume>10</volume>:<fpage>1004</fpage>-<lpage>13</lpage>. <pub-id pub-id-type="doi">10.1097/JTO.0000000000000558</pub-id><pub-id pub-id-type="pmid">25852020</pub-id><pub-id pub-id-type="pmcid">PMC4627490</pub-id></mixed-citation></ref><ref id="r34"><label>34</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zeng</surname><given-names>H</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Z</given-names></name><name name-style="western"><surname>Li</surname><given-names>J</given-names></name><etal/></person-group><article-title>Associations between female lung cancer risk and sex steroid hormones: a systematic review and meta-analysis of the worldwide epidemiological evidence on endogenous and exogenous sex steroid hormones.</article-title><source>BMC Cancer</source><year>2021</year>;<volume>21</volume>:<fpage>690</fpage> .<pub-id pub-id-type="doi">10.1186/s12885-021-08437-9</pub-id><pub-id pub-id-type="pmid">34112140</pub-id><pub-id pub-id-type="pmcid">PMC8194027</pub-id></mixed-citation></ref><ref id="r35"><label>35</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>May</surname><given-names>L</given-names></name><name name-style="western"><surname>Shows</surname><given-names>K</given-names></name><name name-style="western"><surname>Nana-Sinkam</surname><given-names>P</given-names></name><etal/></person-group><article-title>Sex Differences in Lung Cancer.</article-title><source>Cancers (Basel)</source><year>2023</year>;<volume>15</volume>:<fpage>3111</fpage> .<pub-id pub-id-type="doi">10.3390/cancers15123111</pub-id><pub-id pub-id-type="pmid">37370722</pub-id><pub-id pub-id-type="pmcid">PMC10296433</pub-id></mixed-citation></ref><ref id="r36"><label>36</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stapelfeld</surname><given-names>C</given-names></name><name name-style="western"><surname>Neumann</surname><given-names>KT</given-names></name><name name-style="western"><surname>Maser</surname><given-names>E</given-names></name></person-group>. <article-title>Different inhibitory potential of sex hormones on NNK detoxification in vitro: A possible explanation for gender-specific lung cancer risk.</article-title><source>Cancer Lett</source><year>2017</year>;<volume>405</volume>:<fpage>120</fpage>-<lpage>6</lpage>. <pub-id pub-id-type="doi">10.1016/j.canlet.2017.07.016</pub-id><pub-id pub-id-type="pmid">28743530</pub-id></mixed-citation></ref><ref id="r37"><label>37</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><collab>National Lung Screening Trial Research Team</collab></person-group>; Aberle DR, Adams AM, et al. <article-title>Reduced lung-cancer mortality with low-dose computed tomographic screening.</article-title><source>N Engl J Med</source><year>2011</year>;<volume>365</volume>:<fpage>395</fpage>-<lpage>409</lpage>. <pub-id pub-id-type="doi">10.1056/NEJMoa1102873</pub-id><pub-id pub-id-type="pmid">21714641</pub-id><pub-id pub-id-type="pmcid">PMC4356534</pub-id></mixed-citation></ref><ref id="r38"><label>38</label><mixed-citation publication-type="webpage">U.S. Preventative Services Task Force. Lung Cancer: Screening. 2021. Accessed 8/4 2023. Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/lung-cancer-screening" ext-link-type="uri">https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/lung-cancer-screening</ext-link></mixed-citation></ref><ref id="r39"><label>39</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Smeltzer</surname><given-names>MP</given-names></name><name name-style="western"><surname>Liao</surname><given-names>W</given-names></name><name name-style="western"><surname>Faris</surname><given-names>NR</given-names></name><etal/></person-group><article-title>Potential Impact of Criteria Modifications on Race and Sex Disparities in Eligibility for Lung Cancer Screening.</article-title><source>J Thorac Oncol</source><year>2023</year>;<volume>18</volume>:<fpage>158</fpage>-<lpage>68</lpage>. <pub-id pub-id-type="doi">10.1016/j.jtho.2023.02.018</pub-id><pub-id pub-id-type="pmid">36208717</pub-id></mixed-citation></ref><ref id="r40"><label>40</label><mixed-citation publication-type="webpage">National Comprehensive Cancer Network. Lung Cancer Screening. In: NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines. 2023. Accessed August 4, 2023. Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.nccn.org/professionals/physician_gls/pdf/lung_screening.pdf" ext-link-type="uri">https://www.nccn.org/professionals/physician_gls/pdf/lung_screening.pdf</ext-link></mixed-citation></ref><ref id="r41"><label>41</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pinsky</surname><given-names>PF</given-names></name><name name-style="western"><surname>Lau</surname><given-names>YK</given-names></name><name name-style="western"><surname>Doubeni</surname><given-names>CA</given-names></name></person-group>. <article-title>Potential Disparities by Sex and Race or Ethnicity in Lung Cancer Screening Eligibility Rates.</article-title><source>Chest</source><year>2021</year>;<volume>160</volume>:<fpage>341</fpage>-<lpage>50</lpage>. <pub-id pub-id-type="doi">10.1016/j.chest.2021.01.070</pub-id><pub-id pub-id-type="pmid">33545164</pub-id><pub-id pub-id-type="pmcid">PMC8411441</pub-id></mixed-citation></ref><ref id="r42"><label>42</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Warner</surname><given-names>ET</given-names></name><name name-style="western"><surname>Lathan</surname><given-names>CS</given-names></name></person-group>. <article-title>Race and sex differences in patient provider communication and awareness of lung cancer screening in the health information National Trends Survey, 2013-2017.</article-title><source>Prev Med</source><year>2019</year>;<volume>124</volume>:<fpage>84</fpage>-<lpage>90</lpage>. <pub-id pub-id-type="doi">10.1016/j.ypmed.2019.05.001</pub-id><pub-id pub-id-type="pmid">31054908</pub-id></mixed-citation></ref><ref id="r43"><label>43</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ruano-Ravina</surname><given-names>A</given-names></name><name name-style="western"><surname>Provencio</surname><given-names>M</given-names></name><name name-style="western"><surname>Calvo de Juan</surname><given-names>V</given-names></name><etal/></person-group><article-title>Are there differences by sex in lung cancer characteristics at diagnosis? -a nationwide study.</article-title><source>Transl Lung Cancer Res</source><year>2021</year>;<volume>10</volume>:<fpage>3902</fpage>-<lpage>11</lpage>. <pub-id pub-id-type="doi">10.21037/tlcr-21-559</pub-id><pub-id pub-id-type="pmid">34858780</pub-id><pub-id pub-id-type="pmcid">PMC8577975</pub-id></mixed-citation></ref><ref id="r44"><label>44</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tolwin</surname><given-names>Y</given-names></name><name name-style="western"><surname>Gillis</surname><given-names>R</given-names></name><name name-style="western"><surname>Peled</surname><given-names>N.</given-names></name></person-group><article-title>Gender and lung cancer-SEER-based analysis.</article-title><source>Ann Epidemiol</source><year>2020</year>;<volume>46</volume>:<fpage>14</fpage>-<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1016/j.annepidem.2020.04.003</pub-id><pub-id pub-id-type="pmid">32532368</pub-id></mixed-citation></ref><ref id="r45"><label>45</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Araghi</surname><given-names>M</given-names></name><name name-style="western"><surname>Fidler-Benaoudia</surname><given-names>M</given-names></name><name name-style="western"><surname>Arnold</surname><given-names>M</given-names></name><etal/></person-group><article-title>International differences in lung cancer survival by sex, histological type and stage at diagnosis: an ICBP SURVMARK-2 Study.</article-title><source>Thorax</source><year>2022</year>;<volume>77</volume>:<fpage>378</fpage>-<lpage>90</lpage>. <pub-id pub-id-type="doi">10.1136/thoraxjnl-2020-216555</pub-id><pub-id pub-id-type="pmid">34282033</pub-id></mixed-citation></ref><ref id="r46"><label>46</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vaval&#224;</surname><given-names>T</given-names></name><name name-style="western"><surname>Catino</surname><given-names>A</given-names></name><name name-style="western"><surname>Pizzutilo</surname><given-names>P</given-names></name><etal/></person-group><article-title>Gender Differences and Immunotherapy Outcome in Advanced Lung Cancer.</article-title><source>Int J Mol Sci</source><year>2021</year>;<volume>22</volume>:<fpage>11942</fpage> .<pub-id pub-id-type="doi">10.3390/ijms222111942</pub-id><pub-id pub-id-type="pmid">34769372</pub-id><pub-id pub-id-type="pmcid">PMC8584562</pub-id></mixed-citation></ref><ref id="r47"><label>47</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Peng</surname><given-names>J</given-names></name><name name-style="western"><surname>Xu</surname><given-names>X</given-names></name><name name-style="western"><surname>Mace</surname><given-names>BE</given-names></name><etal/></person-group><article-title>Estrogen metabolism within the lung and its modulation by tobacco smoke.</article-title><source>Carcinogenesis</source><year>2013</year>;<volume>34</volume>:<fpage>909</fpage>-<lpage>15</lpage>. <pub-id pub-id-type="doi">10.1093/carcin/bgs402</pub-id><pub-id pub-id-type="pmid">23276798</pub-id><pub-id pub-id-type="pmcid">PMC3616670</pub-id></mixed-citation></ref><ref id="r48"><label>48</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>Y</given-names></name><name name-style="western"><surname>Hecht</surname><given-names>SS</given-names></name></person-group>. <article-title>Metabolic Activation and DNA Interactions of Carcinogenic N-Nitrosamines to Which Humans Are Commonly Exposed.</article-title><source>Int J Mol Sci</source><year>2022</year>;<volume>23</volume>:<fpage>4559</fpage> .<pub-id pub-id-type="doi">10.3390/ijms23094559</pub-id><pub-id pub-id-type="pmid">35562949</pub-id><pub-id pub-id-type="pmcid">PMC9105260</pub-id></mixed-citation></ref><ref id="r49"><label>49</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Skjefstad</surname><given-names>K</given-names></name><name name-style="western"><surname>Richardsen</surname><given-names>E</given-names></name><name name-style="western"><surname>Donnem</surname><given-names>T</given-names></name><etal/></person-group><article-title>The prognostic role of progesterone receptor expression in non-small cell lung cancer patients: Gender-related impacts and correlation with disease-specific survival.</article-title><source>Steroids</source><year>2015</year>;<volume>98</volume>:<fpage>29</fpage>-<lpage>36</lpage>. <pub-id pub-id-type="doi">10.1016/j.steroids.2015.01.020</pub-id><pub-id pub-id-type="pmid">25668612</pub-id></mixed-citation></ref><ref id="r50"><label>50</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gu</surname><given-names>T</given-names></name><name name-style="western"><surname>Wen</surname><given-names>Z</given-names></name><name name-style="western"><surname>Xu</surname><given-names>S</given-names></name><etal/></person-group><article-title>Decreased levels of circulating sex hormones as a biomarker of lung cancer in male patients with solitary pulmonary nodules.</article-title><source>Afr Health Sci</source><year>2014</year>;<volume>14</volume>:<fpage>356</fpage>-<lpage>63</lpage>. <pub-id pub-id-type="doi">10.4314/ahs.v14i2.10</pub-id><pub-id pub-id-type="pmid">25320584</pub-id><pub-id pub-id-type="pmcid">PMC4196406</pub-id></mixed-citation></ref><ref id="r51"><label>51</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ishibashi</surname><given-names>H</given-names></name><name name-style="western"><surname>Suzuki</surname><given-names>T</given-names></name><name name-style="western"><surname>Suzuki</surname><given-names>S</given-names></name><etal/></person-group><article-title>Progesterone receptor in non-small cell lung cancer--a potent prognostic factor and possible target for endocrine therapy.</article-title><source>Cancer Res</source><year>2005</year>;<volume>65</volume>:<fpage>6450</fpage>-<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1158/0008-5472.CAN-04-3087</pub-id><pub-id pub-id-type="pmid">16024650</pub-id></mixed-citation></ref><ref id="r52"><label>52</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stabile</surname><given-names>LP</given-names></name><name name-style="western"><surname>Dacic</surname><given-names>S</given-names></name><name name-style="western"><surname>Land</surname><given-names>SR</given-names></name><etal/></person-group><article-title>Combined analysis of estrogen receptor beta-1 and progesterone receptor expression identifies lung cancer patients with poor outcome.</article-title><source>Clin Cancer Res</source><year>2011</year>;<volume>17</volume>:<fpage>154</fpage>-<lpage>64</lpage>. <pub-id pub-id-type="doi">10.1158/1078-0432.CCR-10-0992</pub-id><pub-id pub-id-type="pmid">21062926</pub-id><pub-id pub-id-type="pmcid">PMC3064257</pub-id></mixed-citation></ref><ref id="r53"><label>53</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fuentes</surname><given-names>N</given-names></name><name name-style="western"><surname>Silveyra</surname><given-names>P</given-names></name></person-group>. <article-title>Estrogen receptor signaling mechanisms.</article-title><source>Adv Protein Chem Struct Biol</source><year>2019</year>;<volume>116</volume>:<fpage>135</fpage>-<lpage>70</lpage>. <pub-id pub-id-type="doi">10.1016/bs.apcsb.2019.01.001</pub-id><pub-id pub-id-type="pmid">31036290</pub-id><pub-id pub-id-type="pmcid">PMC6533072</pub-id></mixed-citation></ref><ref id="r54"><label>54</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xu</surname><given-names>L</given-names></name><name name-style="western"><surname>Wang</surname><given-names>L</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>M</given-names></name></person-group>. <article-title>Identification of genes and pathways associated with sex in Non-smoking lung cancer population.</article-title><source>Gene</source><year>2022</year>;<volume>831</volume>:<elocation-id>146566</elocation-id> .<pub-id pub-id-type="doi">10.1016/j.gene.2022.146566</pub-id><pub-id pub-id-type="pmid">35577039</pub-id></mixed-citation></ref><ref id="r55"><label>55</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nabi</surname><given-names>H</given-names></name><name name-style="western"><surname>Provencher</surname><given-names>L</given-names></name><name name-style="western"><surname>Diorio</surname><given-names>C. RE</given-names></name></person-group>: <article-title>Smoking, Sex, and Non-Small Cell Lung Cancer: Steroid Hormone Receptors in Tumor Tissue (S0424).</article-title><source>J Natl Cancer Inst</source><year>2018</year>;<volume>110</volume>:<fpage>1422</fpage>-<lpage>3</lpage>. <pub-id pub-id-type="doi">10.1093/jnci/djy068</pub-id><pub-id pub-id-type="pmid">29688493</pub-id></mixed-citation></ref><ref id="r56"><label>56</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dubois</surname><given-names>C</given-names></name><name name-style="western"><surname>Rocks</surname><given-names>N</given-names></name><name name-style="western"><surname>Blacher</surname><given-names>S</given-names></name><etal/></person-group><article-title>Lymph/angiogenesis contributes to sex differences in lung cancer through oestrogen receptor alpha signalling.</article-title><source>Endocr Relat Cancer</source><year>2019</year>;<volume>26</volume>:<fpage>201</fpage>-<lpage>16</lpage>. <pub-id pub-id-type="doi">10.1530/ERC-18-0328</pub-id><pub-id pub-id-type="pmid">30444717</pub-id></mixed-citation></ref><ref id="r57"><label>57</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Caetano</surname><given-names>MS</given-names></name><name name-style="western"><surname>Hassane</surname><given-names>M</given-names></name><name name-style="western"><surname>Van</surname><given-names>HT</given-names></name><etal/></person-group><article-title>Sex specific function of epithelial STAT3 signaling in pathogenesis of K-ras mutant lung cancer.</article-title><source>Nat Commun</source><year>2018</year>;<volume>9</volume>:<fpage>4589</fpage> .<pub-id pub-id-type="doi">10.1038/s41467-018-07042-y</pub-id><pub-id pub-id-type="pmid">30389925</pub-id><pub-id pub-id-type="pmcid">PMC6214980</pub-id></mixed-citation></ref><ref id="r58"><label>58</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Klein</surname><given-names>SL</given-names></name><name name-style="western"><surname>Flanagan</surname><given-names>KL</given-names></name></person-group>. <article-title>Sex differences in immune responses.</article-title><source>Nat Rev Immunol</source><year>2016</year>;<volume>16</volume>:<fpage>626</fpage>-<lpage>38</lpage>. <pub-id pub-id-type="doi">10.1038/nri.2016.90</pub-id><pub-id pub-id-type="pmid">27546235</pub-id></mixed-citation></ref><ref id="r59"><label>59</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Raskin</surname><given-names>J</given-names></name><name name-style="western"><surname>Snoeckx</surname><given-names>A</given-names></name><name name-style="western"><surname>Janssens</surname><given-names>A</given-names></name><etal/></person-group><article-title>New Implications of Patients' Sex in Today's Lung Cancer Management.</article-title><source>Cancers (Basel)</source><year>2022</year>;<volume>14</volume>:<fpage>3399</fpage> .<pub-id pub-id-type="doi">10.3390/cancers14143399</pub-id><pub-id pub-id-type="pmid">35884463</pub-id><pub-id pub-id-type="pmcid">PMC9316757</pub-id></mixed-citation></ref><ref id="r60"><label>60</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Conforti</surname><given-names>F</given-names></name><name name-style="western"><surname>Pala</surname><given-names>L</given-names></name><name name-style="western"><surname>Bagnardi</surname><given-names>V</given-names></name><etal/></person-group><article-title>Cancer immunotherapy efficacy and patients' sex: a systematic review and meta-analysis.</article-title><source>Lancet Oncol</source><year>2018</year>;<volume>19</volume>:<fpage>737</fpage>-<lpage>46</lpage>. <pub-id pub-id-type="doi">10.1016/S1470-2045(18)30261-4</pub-id><pub-id pub-id-type="pmid">29778737</pub-id></mixed-citation></ref><ref id="r61"><label>61</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Conforti</surname><given-names>F</given-names></name><name name-style="western"><surname>Pala</surname><given-names>L</given-names></name><name name-style="western"><surname>Pagan</surname><given-names>E</given-names></name><etal/></person-group><article-title>Sex-based differences in response to anti-PD-1 or PD-L1 treatment in patients with non-small-cell lung cancer expressing high PD-L1 levels. A systematic review and meta-analysis of randomized clinical trials.</article-title><source>ESMO Open</source><year>2021</year>;<volume>6</volume>:<elocation-id>100251</elocation-id> .<pub-id pub-id-type="doi">10.1016/j.esmoop.2021.100251</pub-id><pub-id pub-id-type="pmid">34455288</pub-id><pub-id pub-id-type="pmcid">PMC8403740</pub-id></mixed-citation></ref><ref id="r62"><label>62</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>P&#233;rez-D&#237;ez</surname><given-names>I</given-names></name><name name-style="western"><surname>Hidalgo</surname><given-names>MR</given-names></name><name name-style="western"><surname>Malmierca-Merlo</surname><given-names>P</given-names></name><etal/></person-group><article-title>Functional Signatures in Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis of Sex-Based Differences in Transcriptomic Studies.</article-title><source>Cancers (Basel)</source><year>2021</year>;<volume>13</volume>:<fpage>143</fpage> .<pub-id pub-id-type="doi">10.3390/cancers13010143</pub-id><pub-id pub-id-type="pmid">33526761</pub-id><pub-id pub-id-type="pmcid">PMC7796260</pub-id></mixed-citation></ref><ref id="r63"><label>63</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Han</surname><given-names>J</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Li</surname><given-names>X</given-names></name><etal/></person-group><article-title>Pan-cancer analysis reveals sex-specific signatures in the tumor microenvironment.</article-title><source>Mol Oncol</source><year>2022</year>;<volume>16</volume>:<fpage>2153</fpage>-<lpage>73</lpage>. <pub-id pub-id-type="doi">10.1002/1878-0261.13203</pub-id><pub-id pub-id-type="pmid">35229456</pub-id><pub-id pub-id-type="pmcid">PMC9168759</pub-id></mixed-citation></ref><ref id="r64"><label>64</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Behrens</surname><given-names>C</given-names></name><name name-style="western"><surname>Rocha</surname><given-names>P</given-names></name><name name-style="western"><surname>Parra</surname><given-names>ER</given-names></name><etal/></person-group><article-title>Female Gender Predicts Augmented Immune Infiltration in Lung Adenocarcinoma.</article-title><source>Clin Lung Cancer</source><year>2021</year>;<volume>22</volume>:<fpage>e415</fpage>-<lpage>24</lpage>. <pub-id pub-id-type="doi">10.1016/j.cllc.2020.06.003</pub-id><pub-id pub-id-type="pmid">32763065</pub-id></mixed-citation></ref><ref id="r65"><label>65</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Thorsson</surname><given-names>V</given-names></name><name name-style="western"><surname>Gibbs</surname><given-names>DL</given-names></name><name name-style="western"><surname>Brown</surname><given-names>SD</given-names></name><etal/></person-group><article-title>The Immune Landscape of Cancer.</article-title><source>Immunity</source><year>2018</year>;<volume>48</volume>:<fpage>812</fpage>-<lpage>830.e14</lpage>. <pub-id pub-id-type="doi">10.1016/j.immuni.2018.03.023</pub-id><pub-id pub-id-type="pmid">29628290</pub-id><pub-id pub-id-type="pmcid">PMC5982584</pub-id></mixed-citation></ref><ref id="r66"><label>66</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Al Omari</surname><given-names>O</given-names></name><name name-style="western"><surname>Jani</surname><given-names>C</given-names></name><name name-style="western"><surname>Ahmed</surname><given-names>A</given-names></name><etal/></person-group><article-title>Lung Cancer Mortality in the United States between 1999 and 2019: An Observational Analysis of Disparities by Sex and Race.</article-title><source>Ann Am Thorac Soc</source><year>2023</year>;<volume>20</volume>:<fpage>612</fpage>-<lpage>6</lpage>. <pub-id pub-id-type="doi">10.1513/AnnalsATS.202206-510RL</pub-id><pub-id pub-id-type="pmid">36476451</pub-id><pub-id pub-id-type="pmcid">PMC10112410</pub-id></mixed-citation></ref><ref id="r67"><label>67</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Radkiewicz</surname><given-names>C</given-names></name><name name-style="western"><surname>Dickman</surname><given-names>PW</given-names></name><name name-style="western"><surname>Johansson</surname><given-names>ALV</given-names></name><etal/></person-group><article-title>Sex and survival in non-small cell lung cancer: A nationwide cohort study.</article-title><source>PLoS One</source><year>2019</year>;<volume>14</volume>:<elocation-id>e0219206</elocation-id> .<pub-id pub-id-type="doi">10.1371/journal.pone.0219206</pub-id><pub-id pub-id-type="pmid">31247015</pub-id><pub-id pub-id-type="pmcid">PMC6597110</pub-id></mixed-citation></ref><ref id="r68"><label>68</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xiao</surname><given-names>J</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>L</given-names></name><name name-style="western"><surname>He</surname><given-names>B</given-names></name><etal/></person-group><article-title>Impact of Sex and Smoking on the Efficacy of EGFR-TKIs in Terms of Overall Survival in Non-small-Cell Lung Cancer: A Meta-Analysis.</article-title><source>Front Oncol</source><year>2020</year>;<volume>10</volume>:<fpage>1531</fpage> .<pub-id pub-id-type="doi">10.3389/fonc.2020.01531</pub-id><pub-id pub-id-type="pmid">32984005</pub-id><pub-id pub-id-type="pmcid">PMC7477328</pub-id></mixed-citation></ref><ref id="r69"><label>69</label><mixed-citation publication-type="book">Wainer Z, Wright GM, Gough K, et al. Sex-Dependent Staging in Non-Small-Cell Lung Cancer; Analysis of the Effect of Sex Differences in the Eighth Edition of the Tumor, Node, Metastases Staging System. Clin Lung Cancer 2018;19:e933-44.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cllc.2018.08.004</pub-id><pub-id pub-id-type="pmid">30206043</pub-id></mixed-citation></ref><ref id="r70"><label>70</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yoshida</surname><given-names>Y</given-names></name><name name-style="western"><surname>Murayama</surname><given-names>T</given-names></name><name name-style="western"><surname>Sato</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Gender Differences in Long-Term Survival after Surgery for Non-Small Cell Lung Cancer.</article-title><source>Thorac Cardiovasc Surg</source><year>2016</year>;<volume>64</volume>:<fpage>507</fpage>-<lpage>14</lpage>. <pub-id pub-id-type="doi">10.1055/s-0035-1558995</pub-id><pub-id pub-id-type="pmid">26366891</pub-id></mixed-citation></ref><ref id="r71"><label>71</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Watanabe</surname><given-names>K</given-names></name><name name-style="western"><surname>Sakamaki</surname><given-names>K</given-names></name><name name-style="western"><surname>Nishii</surname><given-names>T</given-names></name><etal/></person-group><article-title>Gender Differences in the Recurrence Timing of Patients Undergoing Resection for Non-Small Cell Lung Cancer.</article-title><source>Asian Pac J Cancer Prev</source><year>2018</year>;<volume>19</volume>:<fpage>719</fpage>-<lpage>24</lpage>. <pub-id pub-id-type="doi">10.22034/APJCP.2018.19.3.719</pub-id><pub-id pub-id-type="pmid">29582626</pub-id><pub-id pub-id-type="pmcid">PMC5980847</pub-id></mixed-citation></ref><ref id="r72"><label>72</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ten Haaf</surname><given-names>K</given-names></name><name name-style="western"><surname>van Rosmalen</surname><given-names>J</given-names></name><name name-style="western"><surname>de Koning</surname><given-names>HJ</given-names></name></person-group>. <article-title>Lung cancer detectability by test, histology, stage, and gender: estimates from the NLST and the PLCO trials.</article-title><source>Cancer Epidemiol Biomarkers Prev</source><year>2015</year>;<volume>24</volume>:<fpage>154</fpage>-<lpage>61</lpage>. <pub-id pub-id-type="doi">10.1158/1055-9965.EPI-14-0745</pub-id><pub-id pub-id-type="pmid">25312998</pub-id><pub-id pub-id-type="pmcid">PMC4357842</pub-id></mixed-citation></ref><ref id="r73"><label>73</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yu</surname><given-names>XQ</given-names></name><name name-style="western"><surname>Yap</surname><given-names>ML</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>ES</given-names></name><etal/></person-group><article-title>Evaluating Prognostic Factors for Sex Differences in Lung Cancer Survival: Findings From a Large Australian Cohort.</article-title><source>J Thorac Oncol</source><year>2022</year>;<volume>17</volume>:<fpage>688</fpage>-<lpage>99</lpage>. <pub-id pub-id-type="doi">10.1016/j.jtho.2022.01.016</pub-id><pub-id pub-id-type="pmid">35124253</pub-id></mixed-citation></ref><ref id="r74"><label>74</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Siddiqui</surname><given-names>F</given-names></name><name name-style="western"><surname>Bae</surname><given-names>K</given-names></name><name name-style="western"><surname>Langer</surname><given-names>CJ</given-names></name><etal/></person-group><article-title>The influence of gender, race, and marital status on survival in lung cancer patients: analysis of Radiation Therapy Oncology Group trials.</article-title><source>J Thorac Oncol</source><year>2010</year>;<volume>5</volume>:<fpage>631</fpage>-<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1097/jto.0b013e3181d5e46a</pub-id><pub-id pub-id-type="pmid">20432520</pub-id></mixed-citation></ref><ref id="r75"><label>75</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Woody</surname><given-names>NM</given-names></name><name name-style="western"><surname>Stephans</surname><given-names>KL</given-names></name><name name-style="western"><surname>Andrews</surname><given-names>M</given-names></name><etal/></person-group><article-title>A Histologic Basis for the Efficacy of SBRT to the lung.</article-title><source>J Thorac Oncol</source><year>2017</year>;<volume>12</volume>:<fpage>510</fpage>-<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1016/j.jtho.2016.11.002</pub-id><pub-id pub-id-type="pmid">28017592</pub-id><pub-id pub-id-type="pmcid">PMC7066985</pub-id></mixed-citation></ref><ref id="r76"><label>76</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wainer</surname><given-names>Z</given-names></name><name name-style="western"><surname>Wright</surname><given-names>GM</given-names></name><name name-style="western"><surname>Gough</surname><given-names>K</given-names></name><etal/></person-group><article-title>Impact of sex on prognostic host factors in surgical patients with lung cancer.</article-title><source>ANZ J Surg</source><year>2017</year>;<volume>87</volume>:<fpage>1015</fpage>-<lpage>20</lpage>. <pub-id pub-id-type="doi">10.1111/ans.13728</pub-id><pub-id pub-id-type="pmid">27625078</pub-id></mixed-citation></ref><ref id="r77"><label>77</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sachs</surname><given-names>E</given-names></name><name name-style="western"><surname>Sartipy</surname><given-names>U</given-names></name><name name-style="western"><surname>Jackson</surname><given-names>V.</given-names></name></person-group><article-title>Sex and Survival After Surgery for Lung Cancer: A Swedish Nationwide Cohort.</article-title><source>Chest</source><year>2021</year>;<volume>159</volume>:<fpage>2029</fpage>-<lpage>39</lpage>. <pub-id pub-id-type="doi">10.1016/j.chest.2020.11.010</pub-id><pub-id pub-id-type="pmid">33217414</pub-id><pub-id pub-id-type="pmcid">PMC8129733</pub-id></mixed-citation></ref><ref id="r78"><label>78</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Baum</surname><given-names>P</given-names></name><name name-style="western"><surname>Eichhorn</surname><given-names>ME</given-names></name><name name-style="western"><surname>Diers</surname><given-names>J</given-names></name><etal/></person-group><article-title>Population-Based Analysis of Sex-Dependent Risk Factors for Mortality in Thoracic Surgery for Lung Cancer.</article-title><source>Respiration</source><year>2022</year>;<volume>101</volume>:<fpage>624</fpage>-<lpage>31</lpage>. <pub-id pub-id-type="doi">10.1159/000522045</pub-id><pub-id pub-id-type="pmid">35220299</pub-id></mixed-citation></ref><ref id="r79"><label>79</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tong</surname><given-names>BC</given-names></name><name name-style="western"><surname>Kosinski</surname><given-names>AS</given-names></name><name name-style="western"><surname>Burfeind</surname><given-names>WR</given-names><suffix>Jr</suffix></name><etal/></person-group><article-title>Sex differences in early outcomes after lung cancer resection: analysis of the Society of Thoracic Surgeons General Thoracic Database.</article-title><source>J Thorac Cardiovasc Surg</source><year>2014</year>;<volume>148</volume>:<fpage>13</fpage>-<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1016/j.jtcvs.2014.03.012</pub-id><pub-id pub-id-type="pmid">24726742</pub-id><pub-id pub-id-type="pmcid">PMC4314218</pub-id></mixed-citation></ref><ref id="r80"><label>80</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Boffa</surname><given-names>DJ</given-names></name><name name-style="western"><surname>Allen</surname><given-names>MS</given-names></name><name name-style="western"><surname>Grab</surname><given-names>JD</given-names></name><etal/></person-group><article-title>Data from The Society of Thoracic Surgeons General Thoracic Surgery database: the surgical management of primary lung tumors.</article-title><source>J Thorac Cardiovasc Surg</source><year>2008</year>;<volume>135</volume>:<fpage>247</fpage>-<lpage>54</lpage>. <pub-id pub-id-type="doi">10.1016/j.jtcvs.2007.07.060</pub-id><pub-id pub-id-type="pmid">18242243</pub-id></mixed-citation></ref><ref id="r81"><label>81</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mun</surname><given-names>M</given-names></name><name name-style="western"><surname>Ichinose</surname><given-names>J</given-names></name><name name-style="western"><surname>Matsuura</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Video-assisted thoracoscopic surgery lobectomy via confronting upside-down monitor setting.</article-title><source>J Vis Surg</source><year>2017</year>;<volume>3</volume>:<fpage>129</fpage> .<pub-id pub-id-type="doi">10.21037/jovs.2017.07.08</pub-id><pub-id pub-id-type="pmid">29078689</pub-id><pub-id pub-id-type="pmcid">PMC5638999</pub-id></mixed-citation></ref><ref id="r82"><label>82</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Villamizar</surname><given-names>NR</given-names></name><name name-style="western"><surname>Darrabie</surname><given-names>MD</given-names></name><name name-style="western"><surname>Burfeind</surname><given-names>WR</given-names></name><etal/></person-group><article-title>Thoracoscopic lobectomy is associated with lower morbidity compared with thoracotomy.</article-title><source>J Thorac Cardiovasc Surg</source><year>2009</year>;<volume>138</volume>:<fpage>419</fpage>-<lpage>25</lpage>. <pub-id pub-id-type="doi">10.1016/j.jtcvs.2009.04.026</pub-id><pub-id pub-id-type="pmid">19619789</pub-id></mixed-citation></ref><ref id="r83"><label>83</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Balekian</surname><given-names>AA</given-names></name><name name-style="western"><surname>Wisnivesky</surname><given-names>JP</given-names></name><name name-style="western"><surname>Gould</surname><given-names>MK</given-names></name></person-group>. <article-title>Surgical Disparities Among Patients With Stage I Lung Cancer in the National Lung Screening Trial.</article-title><source>Chest</source><year>2019</year>;<volume>155</volume>:<fpage>44</fpage>-<lpage>52</lpage>. <pub-id pub-id-type="doi">10.1016/j.chest.2018.07.011</pub-id><pub-id pub-id-type="pmid">30056040</pub-id></mixed-citation></ref><ref id="r84"><label>84</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wisnivesky</surname><given-names>JP</given-names></name><name name-style="western"><surname>Henschke</surname><given-names>CI</given-names></name><name name-style="western"><surname>Swanson</surname><given-names>S</given-names></name><etal/></person-group><article-title>Limited resection for the treatment of patients with stage IA lung cancer.</article-title><source>Ann Surg</source><year>2010</year>;<volume>251</volume>:<fpage>550</fpage>-<lpage>4</lpage>. <pub-id pub-id-type="doi">10.1097/SLA.0b013e3181c0e5f3</pub-id><pub-id pub-id-type="pmid">20160639</pub-id></mixed-citation></ref><ref id="r85"><label>85</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Altorki</surname><given-names>N</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X</given-names></name><name name-style="western"><surname>Kozono</surname><given-names>D</given-names></name><etal/></person-group><article-title>Lobar or Sublobar Resection for Peripheral Stage IA Non-Small-Cell Lung Cancer.</article-title><source>N Engl J Med</source><year>2023</year>;<volume>388</volume>:<fpage>489</fpage>-<lpage>98</lpage>. <pub-id pub-id-type="doi">10.1056/NEJMoa2212083</pub-id><pub-id pub-id-type="pmid">36780674</pub-id><pub-id pub-id-type="pmcid">PMC10036605</pub-id></mixed-citation></ref><ref id="r86"><label>86</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Saji</surname><given-names>H</given-names></name><name name-style="western"><surname>Okada</surname><given-names>M</given-names></name><name name-style="western"><surname>Tsuboi</surname><given-names>M</given-names></name><etal/></person-group><article-title>Segmentectomy versus lobectomy in small-sized peripheral non-small-cell lung cancer (JCOG0802/WJOG4607L): a multicentre, open-label, phase 3, randomised, controlled, non-inferiority trial.</article-title><source>Lancet</source><year>2022</year>;<volume>399</volume>:<fpage>1607</fpage>-<lpage>17</lpage>. <pub-id pub-id-type="doi">10.1016/S0140-6736(21)02333-3</pub-id><pub-id pub-id-type="pmid">35461558</pub-id></mixed-citation></ref><ref id="r87"><label>87</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Deng</surname><given-names>HY</given-names></name><name name-style="western"><surname>Liu</surname><given-names>C</given-names></name><name name-style="western"><surname>Qiu</surname><given-names>XM</given-names></name><etal/></person-group><article-title>Assessing Differences in Lymph Node Metastasis Based Upon Sex in Early Non-Small Cell Lung Cancer.</article-title><source>World J Surg</source><year>2021</year>;<volume>45</volume>:<fpage>2610</fpage>-<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1007/s00268-021-06136-x</pub-id><pub-id pub-id-type="pmid">33899137</pub-id></mixed-citation></ref><ref id="r88"><label>88</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>McGuire</surname><given-names>AL</given-names></name><name name-style="western"><surname>McConechy</surname><given-names>MK</given-names></name><name name-style="western"><surname>Melosky</surname><given-names>BL</given-names></name><etal/></person-group><article-title>The Clinically Actionable Molecular Profile of Early versus Late-Stage Non-Small Cell Lung Cancer, an Individual Age and Sex Propensity-Matched Pair Analysis.</article-title><source>Curr Oncol</source><year>2022</year>;<volume>29</volume>:<fpage>2630</fpage>-<lpage>43</lpage>. <pub-id pub-id-type="doi">10.3390/curroncol29040215</pub-id><pub-id pub-id-type="pmid">35448189</pub-id><pub-id pub-id-type="pmcid">PMC9031556</pub-id></mixed-citation></ref><ref id="r89"><label>89</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Baum</surname><given-names>P</given-names></name><name name-style="western"><surname>Winter</surname><given-names>H</given-names></name><name name-style="western"><surname>Eichhorn</surname><given-names>ME</given-names></name><etal/></person-group><article-title>Trends in age- and sex-specific lung cancer mortality in Europe and Northern America: Analysis of vital registration data from the WHO Mortality Database between 2000 and 2017.</article-title><source>Eur J Cancer</source><year>2022</year>;<volume>171</volume>:<fpage>269</fpage>-<lpage>79</lpage>. <pub-id pub-id-type="doi">10.1016/j.ejca.2022.05.011</pub-id><pub-id pub-id-type="pmid">35738973</pub-id></mixed-citation></ref><ref id="r90"><label>90</label><mixed-citation publication-type="webpage">National Comprehensive Cancer Network. Non-Small Cell Lung Cancer. In: NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines). 2023. Accessed September 7, 2023. Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf" ext-link-type="uri">https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf</ext-link></mixed-citation></ref><ref id="r91"><label>91</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tsai</surname><given-names>LL</given-names></name><name name-style="western"><surname>Chu</surname><given-names>NQ</given-names></name><name name-style="western"><surname>Blessing</surname><given-names>WA</given-names></name><etal/></person-group><article-title>Lung Cancer in Women.</article-title><source>Ann Thorac Surg</source><year>2022</year>;<volume>114</volume>:<fpage>1965</fpage>-<lpage>73</lpage>. <pub-id pub-id-type="doi">10.1016/j.athoracsur.2021.09.060</pub-id><pub-id pub-id-type="pmid">34742731</pub-id></mixed-citation></ref><ref id="r92"><label>92</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pinto</surname><given-names>JA</given-names></name><name name-style="western"><surname>Vallejos</surname><given-names>CS</given-names></name><name name-style="western"><surname>Raez</surname><given-names>LE</given-names></name><etal/></person-group><article-title>Gender and outcomes in non-small cell lung cancer: an old prognostic variable comes back for targeted therapy and immunotherapy?</article-title><source>ESMO Open</source><year>2018</year>;<volume>3</volume>:<elocation-id>e000344</elocation-id> .<pub-id pub-id-type="doi">10.1136/esmoopen-2018-000344</pub-id><pub-id pub-id-type="pmid">29682332</pub-id><pub-id pub-id-type="pmcid">PMC5905840</pub-id></mixed-citation></ref><ref id="r93"><label>93</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Huang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Cho</surname><given-names>HJ</given-names></name><name name-style="western"><surname>Stranger</surname><given-names>BE</given-names></name><etal/></person-group><article-title>Sex dimorphism in response to targeted therapy and immunotherapy in non-small cell lung cancer patients: a narrative review.</article-title><source>Transl Lung Cancer Res</source><year>2022</year>;<volume>11</volume>:<fpage>920</fpage>-<lpage>34</lpage>. <pub-id pub-id-type="doi">10.21037/tlcr-21-1013</pub-id><pub-id pub-id-type="pmid">35693273</pub-id><pub-id pub-id-type="pmcid">PMC9186178</pub-id></mixed-citation></ref><ref id="r94"><label>94</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Isla</surname><given-names>D</given-names></name><name name-style="western"><surname>Majem</surname><given-names>M</given-names></name><name name-style="western"><surname>Vi&#241;olas</surname><given-names>N</given-names></name><etal/></person-group><article-title>A consensus statement on the gender perspective in lung cancer.</article-title><source>Clin Transl Oncol</source><year>2017</year>;<volume>19</volume>:<fpage>527</fpage>-<lpage>35</lpage>. <pub-id pub-id-type="doi">10.1007/s12094-016-1578-x</pub-id><pub-id pub-id-type="pmid">27885542</pub-id></mixed-citation></ref><ref id="r95"><label>95</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Remon</surname><given-names>J</given-names></name><name name-style="western"><surname>Pignataro</surname><given-names>D</given-names></name><name name-style="western"><surname>Novello</surname><given-names>S</given-names></name><etal/></person-group><article-title>Current treatment and future challenges in ROS1- and ALK-rearranged advanced non-small cell lung cancer.</article-title><source>Cancer Treat Rev</source><year>2021</year>;<volume>95</volume>:<elocation-id>102178</elocation-id> .<pub-id pub-id-type="doi">10.1016/j.ctrv.2021.102178</pub-id><pub-id pub-id-type="pmid">33743408</pub-id></mixed-citation></ref><ref id="r96"><label>96</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Conforti</surname><given-names>F</given-names></name><name name-style="western"><surname>Pala</surname><given-names>L</given-names></name><name name-style="western"><surname>Bagnardi</surname><given-names>V</given-names></name><etal/></person-group><article-title>Sex-Based Heterogeneity in Response to Lung Cancer Immunotherapy: A Systematic Review and Meta-Analysis.</article-title><source>J Natl Cancer Inst</source><year>2019</year>;<volume>111</volume>:<fpage>772</fpage>-<lpage>81</lpage>. <pub-id pub-id-type="doi">10.1093/jnci/djz094</pub-id><pub-id pub-id-type="pmid">31106827</pub-id><pub-id pub-id-type="pmcid">PMC6695312</pub-id></mixed-citation></ref><ref id="r97"><label>97</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>C</given-names></name><name name-style="western"><surname>Qiao</surname><given-names>W</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Effect of sex on the efficacy of patients receiving immune checkpoint inhibitors in advanced non-small cell lung cancer.</article-title><source>Cancer Med</source><year>2019</year>;<volume>8</volume>:<fpage>4023</fpage>-<lpage>31</lpage>. <pub-id pub-id-type="doi">10.1002/cam4.2280</pub-id><pub-id pub-id-type="pmid">31165589</pub-id><pub-id pub-id-type="pmcid">PMC6639192</pub-id></mixed-citation></ref><ref id="r98"><label>98</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xue</surname><given-names>C</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>S</given-names></name><name name-style="western"><surname>Dong</surname><given-names>H</given-names></name><etal/></person-group><article-title>Association Between Efficacy of Immune Checkpoint Inhibitors and Sex: An Updated Meta-Analysis on 21 Trials and 12,675 Non-Small Cell Lung Cancer Patients.</article-title><source>Front Oncol</source><year>2021</year>;<volume>11</volume>:<elocation-id>627016</elocation-id> .<pub-id pub-id-type="doi">10.3389/fonc.2021.627016</pub-id><pub-id pub-id-type="pmid">34513654</pub-id><pub-id pub-id-type="pmcid">PMC8427763</pub-id></mixed-citation></ref><ref id="r99"><label>99</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liang</surname><given-names>J</given-names></name><name name-style="western"><surname>Hong</surname><given-names>J</given-names></name><name name-style="western"><surname>Tang</surname><given-names>X</given-names></name><etal/></person-group><article-title>Sex difference in response to non-small cell lung cancer immunotherapy: an updated meta-analysis.</article-title><source>Ann Med</source><year>2022</year>;<volume>54</volume>:<fpage>2606</fpage>-<lpage>16</lpage>. <pub-id pub-id-type="doi">10.1080/07853890.2022.2124449</pub-id><pub-id pub-id-type="pmid">36128737</pub-id><pub-id pub-id-type="pmcid">PMC9518269</pub-id></mixed-citation></ref><ref id="r100"><label>100</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Madala</surname><given-names>S</given-names></name><name name-style="western"><surname>Rasul</surname><given-names>R</given-names></name><name name-style="western"><surname>Singla</surname><given-names>K</given-names></name><etal/></person-group><article-title>Gender Differences and Their Effects on Survival Outcomes in Lung Cancer Patients Treated With PD-1/PD-L1 Checkpoint Inhibitors: A Systematic Review and Meta-Analysis.</article-title><source>Clin Oncol (R Coll Radiol)</source><year>2022</year>;<volume>34</volume>:<fpage>799</fpage>-<lpage>809</lpage>. <pub-id pub-id-type="doi">10.1016/j.clon.2022.03.010</pub-id><pub-id pub-id-type="pmid">35400597</pub-id></mixed-citation></ref><ref id="r101"><label>101</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Takada</surname><given-names>K</given-names></name><name name-style="western"><surname>Shimokawa</surname><given-names>M</given-names></name><name name-style="western"><surname>Mizuki</surname><given-names>F</given-names></name><etal/></person-group><article-title>Association between sex and outcomes in patients with non-small-cell lung cancer receiving combination chemoimmunotherapy as a first-line therapy: a systematic review and meta-analysis of randomized clinical trials.</article-title><source>Eur J Med Res</source><year>2022</year>;<volume>27</volume>:<fpage>157</fpage> .<pub-id pub-id-type="doi">10.1186/s40001-022-00789-7</pub-id><pub-id pub-id-type="pmid">35999618</pub-id><pub-id pub-id-type="pmcid">PMC9400263</pub-id></mixed-citation></ref><ref id="r102"><label>102</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Duma</surname><given-names>N</given-names></name><name name-style="western"><surname>Abdel-Ghani</surname><given-names>A</given-names></name><name name-style="western"><surname>Yadav</surname><given-names>S</given-names></name><etal/></person-group><article-title>Sex Differences in Tolerability to Anti-Programmed Cell Death Protein 1 Therapy in Patients with Metastatic Melanoma and Non-Small Cell Lung Cancer: Are We All Equal?</article-title><source>Oncologist</source><year>2019</year>;<volume>24</volume>:<fpage>e1148</fpage>-<lpage>55</lpage>. <pub-id pub-id-type="doi">10.1634/theoncologist.2019-0094</pub-id><pub-id pub-id-type="pmid">31036771</pub-id><pub-id pub-id-type="pmcid">PMC6853107</pub-id></mixed-citation></ref></ref-list></back></article></pmc-articleset>